var title_f36_31_37360="Barretts high-grade AF";
var content_f36_31_37360=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F66867&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F66867&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 527px\">",
"   <div class=\"ttl\">",
"    Autofluorescence image of Barrett's esophagus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 507px; height: 226px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    White light endoscopic view of Barrett's esophagus (left panel) showing a focal lesion (arrow) with high grade dysplasia. Corresponding autofluorescence image (right panel) showing the focal lesion (arrow). This lesion was first detected by autofluorescence and only retrospectively seen with white light imaging.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: KARA, et al. Gastrointestinal Endoscopy 2005; 61:679.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_31_37360=[""].join("\n");
var outline_f36_31_37360=null;
var title_f36_31_37361="Avulsion fracture of thumb proximal phalanx";
var content_f36_31_37361=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RADIOL%2F86891&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RADIOL%2F86891&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 617px\">",
"   <div class=\"ttl\">",
"    Avulsion fracture and ulnar collateral ligament injury of the thumb",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 597px; height: 298px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Three views of the right hand in posteroanterior (A), oblique (B), and lateral (C) projections demonstrate a non-displaced fracture at the ulnar base of the first proximal phalanx with intra-articular extension to the metacarpophalangeal (MCP) joint (white arrowhead), indicative of an ulnar collateral ligament injury with associated avulsion fracture secondary to forced hyperabduction of the flexed thumb. Associated soft tissue swelling of the thenar eminence is shown (C, white arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Robert Ward, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_31_37361=[""].join("\n");
var outline_f36_31_37361=null;
var title_f36_31_37362="LBP sciatica chart";
var content_f36_31_37362=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F50346&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F50346&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 626px\">",
"   <div class=\"ttl\">",
"    Diagnostic algorithm of low back pain",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 606px; height: 665px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     ESR: erythrocyte sedimentation rate.",
"     <br/>",
"     * Some clinicians obtain C-reactive protein test in addition to ESR as an inflammatory marker.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_31_37362=[""].join("\n");
var outline_f36_31_37362=null;
var title_f36_31_37363="Patient information: Glomerular disease (The Basics)";
var content_f36_31_37363=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/17206\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?26/28/27072\">",
"         Anatomy of the urinary tract",
"        </a>",
"        <li>",
"         <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?0/5/93\">",
"          Hemodialysis",
"         </a>",
"         <li>",
"          <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?25/22/25952\">",
"           Peritoneal dialysis",
"          </a>",
"          <li>",
"           <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?36/59/37809\">",
"            Kidney transplant",
"           </a>",
"          </li>",
"         </li>",
"        </li>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?5/46/5859\">",
"         Patient information: Acute kidney failure (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?22/59/23474\">",
"         Patient information: Blood in the urine (hematuria) in adults (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?27/35/28212\">",
"         Patient information: Chronic kidney disease (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?25/1/25619\">",
"         Patient information: Hemodialysis (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?33/58/34722\">",
"         Patient information: High blood pressure in adults (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?24/46/25315\">",
"         Patient information: Kidney transplant (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?22/40/23171\">",
"         Patient information: Medicines for high blood pressure (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?15/43/16051\">",
"         Patient information: Peritoneal dialysis (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?20/42/21155\">",
"         Patient information: Swelling (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?9/53/10066\">",
"         Patient information: Blood in the urine (hematuria) in adults (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?1/9/1169\">",
"         Patient information: Blood in the urine (hematuria) in children (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?13/5/13398\">",
"         Patient information: Chronic kidney disease (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?31/53/32594\">",
"         Patient information: Edema (swelling) (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?36/35/37426\">",
"         Patient information: Glomerular disease overview (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?39/57/40852\">",
"         Patient information: Hemodialysis (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?36/32/37380\">",
"         Patient information: High blood pressure treatment in adults (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?0/58/931\">",
"         Patient information: High blood pressure treatment in children (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?14/10/14501\">",
"         Patient information: Peritoneal dialysis (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Glomerular disease (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/glomerular-disease-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H14390937\">",
"      <span class=\"h1\">",
"       What is glomerular disease?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Glomerular disease is a condition that affects the kidneys. The kidneys are organs in the urinary tract that make urine (",
"      <a class=\"graphic graphic_figure graphicRef79864 \" href=\"mobipreview.htm?26/28/27072\">",
"       figure 1",
"      </a>",
"      ). Each kidney has 2 parts:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        A part that filters the blood and removes waste and excess salt and water",
"       </li>",
"       <li>",
"        A part that collects urine",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      In glomerular disease, the part of the kidney that filters the blood doesn&rsquo;t work normally. As a result, substances that shouldn&rsquo;t be in the urine, such as blood and protein, can get into the urine.",
"     </p>",
"     <p>",
"      Glomerular disease can happen quickly or slowly over time. There are different types of glomerular disease, and each type has different causes.",
"     </p>",
"     <p>",
"      Sometimes glomerular disease causes serious problems. It can cause acute kidney failure, which is when the kidneys suddenly stop working. It can also cause chronic kidney disease, which is when the kidneys slowly stop working.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H14390952\">",
"      <span class=\"h1\">",
"       What are the symptoms of glomerular disease?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The symptoms depend on the type of glomerular disease you have and what&rsquo;s causing it. Some people with glomerular disease have no symptoms. They find out they have it when their doctor does a urine test for another reason.",
"     </p>",
"     <p>",
"      When glomerular disease causes symptoms, they can include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Bloody urine or urine that is red, pink, or brown",
"       </li>",
"       <li>",
"        Foamy-looking urine",
"       </li>",
"       <li>",
"        Swelling of the hands, face, feet, or belly",
"       </li>",
"       <li>",
"        Feeling tired",
"       </li>",
"       <li>",
"        Urinating less than usual",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H14390967\">",
"      <span class=\"h1\">",
"       Is there a test for glomerular disease?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. Your doctor or nurse can check for glomerular disease by doing blood and urine tests. These tests can show if your urine has blood or protein in it, and how well your kidneys are working.",
"     </p>",
"     <p>",
"      Your doctor or nurse will probably do other tests to find out which type of glomerular disease you have. These tests can include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Blood tests to check for medical conditions that can cause glomerular disease",
"       </li>",
"       <li>",
"        An ultrasound of your kidney &ndash; An ultrasound is an imaging test that uses sound waves to create a picture of the kidney.",
"       </li>",
"       <li>",
"        A kidney biopsy &ndash; During a biopsy, the doctor will put a thin needle into your back and into your kidney. He or she will remove a tiny sample of tissue from the kidney. Then another doctor will look at the sample under a microscope.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H14390982\">",
"      <span class=\"h1\">",
"       How is glomerular disease treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Treatment depends on your symptoms, what&rsquo;s causing your glomerular disease, and how quickly it happened.",
"     </p>",
"     <p>",
"      People with mild glomerular disease might not need treatment. But their doctor will do blood and urine tests over time to follow their condition.",
"     </p>",
"     <p>",
"      Some types of glomerular disease go away on their own. For instance, people can get glomerular disease after they have an infection in another part of their body. This type of glomerular disease usually goes away after the infection is treated.",
"     </p>",
"     <p>",
"      When glomerular disease does need to be treated, treatments can include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Medicines called steroids &ndash; These steroids are different from the ones athletes take to build muscle. These medicines can come as pills or go into a vein through a tube called an &ldquo;IV.&rdquo;",
"       </li>",
"       <li>",
"        Medicines that treat high blood pressure",
"       </li>",
"       <li>",
"        Medicines called &ldquo;diuretics&rdquo; that make people urinate a lot",
"       </li>",
"       <li>",
"        Plasmapheresis &ndash; For this treatment, a machine pumps blood from your body and filters out substances that are harming your kidney. Then the machine returns the blood to your body.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      People whose kidneys have stopped working might need other treatment called &ldquo;renal replacement therapy.&rdquo; Renal replacement therapy includes 3 different treatments that can do the work of the kidneys. These treatments are:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Hemodialysis &ndash; Hemodialysis is a procedure in which a machine pumps blood out of the body, filters it, and returns it to the body (",
"        <a class=\"graphic graphic_figure graphicRef56992 \" href=\"mobipreview.htm?0/5/93\">",
"         figure 2",
"        </a>",
"        ). People have hemodialysis at least 3 times a week.",
"       </li>",
"       <li>",
"        Peritoneal dialysis &ndash; Peritoneal dialysis is a procedure that people do at home every day. It involves piping a special fluid through a tube into the belly. This fluid collects waste and excess salt and water from the blood. Then the used fluid drains out of the belly (",
"        <a class=\"graphic graphic_figure graphicRef71539 \" href=\"mobipreview.htm?25/22/25952\">",
"         figure 3",
"        </a>",
"        ).",
"       </li>",
"       <li>",
"        Kidney transplant &ndash; A kidney transplant is surgery in which a doctor puts a healthy kidney in a person whose kidneys are diseased (",
"        <a class=\"graphic graphic_figure graphicRef59957 \" href=\"mobipreview.htm?36/59/37809\">",
"         figure 4",
"        </a>",
"        ).",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H14390997\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?22/59/23474?source=see_link\">",
"       Patient information: Blood in the urine (hematuria) in adults (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?20/42/21155?source=see_link\">",
"       Patient information: Swelling (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?33/58/34722?source=see_link\">",
"       Patient information: High blood pressure in adults (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?22/40/23171?source=see_link\">",
"       Patient information: Medicines for high blood pressure (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?5/46/5859?source=see_link\">",
"       Patient information: Acute kidney failure (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?27/35/28212?source=see_link\">",
"       Patient information: Chronic kidney disease (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?25/1/25619?source=see_link\">",
"       Patient information: Hemodialysis (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?15/43/16051?source=see_link\">",
"       Patient information: Peritoneal dialysis (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?24/46/25315?source=see_link\">",
"       Patient information: Kidney transplant (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?36/35/37426?source=see_link\">",
"       Patient information: Glomerular disease overview (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?9/53/10066?source=see_link\">",
"       Patient information: Blood in the urine (hematuria) in adults (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?1/9/1169?source=see_link\">",
"       Patient information: Blood in the urine (hematuria) in children (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?31/53/32594?source=see_link\">",
"       Patient information: Edema (swelling) (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?13/5/13398?source=see_link\">",
"       Patient information: Chronic kidney disease (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?36/32/37380?source=see_link\">",
"       Patient information: High blood pressure treatment in adults (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?0/58/931?source=see_link\">",
"       Patient information: High blood pressure treatment in children (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?39/57/40852?source=see_link\">",
"       Patient information: Hemodialysis (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?14/10/14501?source=see_link\">",
"       Patient information: Peritoneal dialysis (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"mobipreview.htm?36/31/37363?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 17206 Version 2.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-190.111.122.2-74CF0474CE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_31_37363=[""].join("\n");
var outline_f36_31_37363=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14390937\">",
"      What is glomerular disease?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14390952\">",
"      What are the symptoms of glomerular disease?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14390967\">",
"      Is there a test for glomerular disease?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14390982\">",
"      How is glomerular disease treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14390997\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/17206\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?26/28/27072\">",
"      Anatomy of the urinary tract",
"     </a>",
"     <li>",
"      <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?0/5/93\">",
"       Hemodialysis",
"      </a>",
"      <li>",
"       <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?25/22/25952\">",
"        Peritoneal dialysis",
"       </a>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?36/59/37809\">",
"         Kidney transplant",
"        </a>",
"       </li>",
"      </li>",
"     </li>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?5/46/5859?source=related_link\">",
"      Patient information: Acute kidney failure (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?9/53/10066?source=related_link\">",
"      Patient information: Blood in the urine (hematuria) in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?22/59/23474?source=related_link\">",
"      Patient information: Blood in the urine (hematuria) in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?1/9/1169?source=related_link\">",
"      Patient information: Blood in the urine (hematuria) in children (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?13/5/13398?source=related_link\">",
"      Patient information: Chronic kidney disease (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?27/35/28212?source=related_link\">",
"      Patient information: Chronic kidney disease (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?31/53/32594?source=related_link\">",
"      Patient information: Edema (swelling) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?36/35/37426?source=related_link\">",
"      Patient information: Glomerular disease overview (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?39/57/40852?source=related_link\">",
"      Patient information: Hemodialysis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?25/1/25619?source=related_link\">",
"      Patient information: Hemodialysis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?33/58/34722?source=related_link\">",
"      Patient information: High blood pressure in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?36/32/37380?source=related_link\">",
"      Patient information: High blood pressure treatment in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?0/58/931?source=related_link\">",
"      Patient information: High blood pressure treatment in children (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?24/46/25315?source=related_link\">",
"      Patient information: Kidney transplant (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?22/40/23171?source=related_link\">",
"      Patient information: Medicines for high blood pressure (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?14/10/14501?source=related_link\">",
"      Patient information: Peritoneal dialysis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?15/43/16051?source=related_link\">",
"      Patient information: Peritoneal dialysis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?20/42/21155?source=related_link\">",
"      Patient information: Swelling (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_31_37364="12-lead ECG right posteroseptal WPW III";
var content_f36_31_37364=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F59055&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F59055&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 535px\">",
"   <div class=\"ttl\">",
"    12-lead electrocardiogram (ECG) of a right posteroseptal accessory AV pathway",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 515px; height: 316px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The 12 lead ECG during rapid atrial pacing shows QRS complexes that are maximally preexcited; the complexes have a pattern suggesting an AV accessory pathway located in the right posteroseptal area. At the time of ablation, the pathway was localized to the midseptal region.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_31_37364=[""].join("\n");
var outline_f36_31_37364=null;
var title_f36_31_37365="Belimumab: Drug information";
var content_f36_31_37365=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Belimumab: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?19/48/20228?source=see_link\">",
"    see \"Belimumab: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block spa drugH1Div\" id=\"F14283838\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Special Alerts",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Health Canada Issues Notice Regarding Hypersensitivity and Infusion Reactions",
"     </span>",
"     <span class=\"collapsible-date\">",
"      May 2012",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       GlaxoSmithKline Inc, in conjunction with Health Canada, has notified healthcare practitioners that belimumab Canadian product monograph has been updated in response to reports of serious (including fatal) hypersensitivity and infusion-related reactions observed with belimumab administration. Hypersensitivity reactions with a delayed onset of up to several hours (eg, 4 hours) after belimumab administration have been reported. The manufacturer notes that during clinical trials, similar reactions reported in ~1% of patients, were observed more often during or shortly after administration.",
"      </p>",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       Healthcare providers are being reminded of the following:",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"       - The risk of a reaction may be increased in patients with multiple drug allergies or significant hypersensitivity. Reactions occur most often with the first two infusions and decrease with subsequent infusions.",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"       - Therapy should be prescribed, managed, and administered by qualified healthcare providers.",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"       - Monitor patients during and for an appropriate amount of time following administration of belimumab (keeping in mind the potential for delayed-onset reactions).",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"       - Stop belimumab infusion and initiate appropriate medical management in the event of a severe reaction.",
"      </p>",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       Further information may be found at file://hc-sc.gc.ca/dhp-mps/medeff/advisories-avis/prof/_2012/benlysta_hpc-cps-eng.php",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F12603131\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Benlysta&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F13243915\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Benlysta&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F12617225\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Monoclonal Antibody",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F12617293\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Systemic lupus erythematosus (SLE):",
"     </b>",
"     I.V.: Initial: 10 mg/kg every 2 weeks for 3 doses; Maintenance: 10 mg/kg every 4 weeks",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F12617294\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F12617449\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">",
"     No dosage adjustment is necessary for Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &ge;15 mL/minute; has not been studied in Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;15 mL/minute",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F12617450\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling (has not been studied).",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F12618780\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Benlysta&reg;: 120 mg, 400 mg [contains polysorbate 80, sucrose 80 mg/mL]",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F12617223\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM247030.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM247030.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F12617301\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer intravenously over 1 hour through a dedicated I.V. line. Do",
"     <b>",
"      NOT",
"     </b>",
"     administer as an I.V. push or bolus. Discontinue infusion for severe hypersensitivity reaction (eg, anaphylaxis, angioedema). The infusion may be slowed or temporarily interrupted for minor reactions. Consider premedicating with an antihistamine and antipyretic for prophylaxis against hypersensitivity or infusion reactions.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F12617284\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Incompatible",
"     </b>",
"     Dextrose-containing solutions",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F12617226\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of autoantibody-positive (antinuclear antibody [ANA] and/or antidouble-stranded DNA [anti-ds-DNA]) active systemic lupus erythematosus (SLE) in addition to standard therapy",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F12617259\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Nausea (15%), diarrhea (12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Miscellaneous: Infusion-related reaction (17%), hypersensitivity (13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &ge;3% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Fever (10%), insomnia (6% to 7%), migraine (5%), depression (5% to 6%), anxiety (4%), headache (&ge;3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dermatologic: Skin reactions (&ge;3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Viral gastroenteritis (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Genitourinary: Urinary tract infection (site not specified &gt;5%), cystitis (4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hematologic: Leukopenia (4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Neuromuscular &amp; skeletal: Pain in extremity (6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Respiratory: Bronchitis (9%), nasopharyngitis (9%), pharyngitis (5%), sinusitis (&gt;5%), upper respiratory infection (&gt;5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Miscellaneous: Influenza (&gt;5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &lt;3% (Limited to important or life-threatening): Anaphylaxis (including fatalities), angioedema, antibody formation, bradycardia, cellulitis, dyspnea, eyelid edema, hypotension, myalgia, pneumonia, pruritus, rash, suicide, urticaria",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F12617230\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity (anaphylaxis) to belimumab or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F12617231\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypersensitivity/infusion reactions: Serious hypersensitivity reactions including anaphylaxis (with fatalities) and other reactions (eg, angioedema, hypotension, urticaria, pruritus, or dyspnea) have been reported; onset may be delayed. Risk for hypersensitivity reactions may be increased with history of multiple drug allergies or significant hypersensitivity. Infusion-related reactions (which may be difficult to distinguish from hypersensitivity) may also occur; symptoms may include bradycardia, hypotension, myalgia, headache, rash, and urticaria. Monitor for hypersensitivity and infusion-related reactions for an appropriate time following administration and immediately discontinue for severe reactions (and administer appropriate medical treatment) or slow or temporarily interrupt infusion for other infusion reactions It is unknown if premedication prevents or reduces the severity of hypersensitivity reactions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Infections: Serious and potentially fatal infections may occur during treatment. Use with caution in patients with chronic infections; treatment should not be undertaken if receiving therapy for chronic infection. Consider discontinuing interrupting belimumab in patients who develop new infections and initiate appropriate anti-infective treatment; monitor closely.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Malignancy: Immunosuppressant therapy may increase the risk of malignancy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Mortality: Deaths due to infection, cardiovascular disease, and suicide were higher in belimumab patients compared to placebo during clinical trials.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Psychiatric events: The most common symptoms reported included anxiety, depression, and/or insomnia. New onset or worsening of existing depression, and suicide, has been reported; most patients had a history of a psychiatric disorder and were already receiving treatment. Monitor for new or worsening depression, suicidal ideation or other mood changes.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Immunomodulators: Use of belimumab with other immune modifying biologic therapy (including those targeting B-cells) or with intravenous cyclophosphamide has not been studied; combined use is not recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Immunizations: Live vaccines should not be given within 30 days before or concurrently with belimumab; there is no data available concerning secondary transmission of infection from live vaccines.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Black/African-American patients: May have a lower response rate.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Has not been studied in patients with severe active lupus nephritis or severe active CNS lupus; use not recommended.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298821\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F12757376\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Abatacept: May enhance the adverse/toxic effect of Belimumab.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Abciximab: May enhance the potential for allergic or hypersensitivity reactions to Monoclonal Antibodies. Also may cause thrombocytopenia or diminished therapeutic effects.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Immunosuppressants may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Belatacept: May enhance the adverse/toxic effect of Belimumab.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Coccidioidin Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioidin Skin Test.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cyclophosphamide: Belimumab may enhance the adverse/toxic effect of Cyclophosphamide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Denileukin Diftitox: May enhance the adverse/toxic effect of Belimumab.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Echinacea: May diminish the therapeutic effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Etanercept: May enhance the adverse/toxic effect of Belimumab.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Monoclonal Antibodies: May enhance the adverse/toxic effect of Belimumab.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or other non-disease modifying antirheumatic drugs (non-DMARDs) is permitted, and this warning seems to particularly focused on more potent immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Inactivated): Belimumab may diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Vaccinial infections may develop. Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Live): Belimumab may enhance the adverse/toxic effect of Vaccines (Live).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F12617227\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F12617228\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were observed in some animal reproduction studies. IgG molecules are known to cross the placenta (belimumab is an engineered IgG molecule). Effective contraception should be used during and for at least 4 months following treatment in women of childbearing potential. Healthcare providers are encouraged to enroll women exposed to belimumab during pregnancy in a pregnancy registry (877-681-6296); patients may also enroll themselves.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F12617229\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F16257698\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is not known if belimumab is excreted in breast milk. Because IgG molecules are excreted in breast milk, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of treatment to the mother.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16322894\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Benlysta Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     120 mg (1): $531.82",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     400 mg (1): $1772.71",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F12617303\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Monitor for hypersensitivity or infusion reactions; infections; worsening of depression, mood changes, or suicidal thoughts",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F13733205\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Benlysta (CZ, DK, EE, GB, NO, SE)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F12617285\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Belimumab is an IgG1-lambda monoclonal antibody that prevents the survival of B lymphocytes by blocking the binding of soluble human B lymphocyte stimulator protein (BLyS) to receptors on B lymphocytes. This reduces the activity of B-cell mediated immunity and the autoimmune response.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F12617287\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Onset of action: B cells: 8 weeks; Clinical improvement (SLE Responder Index and flare reduction): 16 weeks (Navarra, 2011)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 5.29 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life elimination: 19.4 days",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Furie R, Petri M, Zamani O, et al, &ldquo;A Phase III, Randomized, Placebo-Controlled Study of Belimumab, a Monoclonal Antibody That Inhibits B Lymphocyte Stimulator, in Patients With Systemic Lupus Erythematosus,&rdquo;",
"      <i>",
"       Arthritis Rheum",
"      </i>",
"      , 2011, 63(12):3918-30.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/31/37365/abstract-text/22127708/pubmed\" id=\"22127708\" target=\"_blank\">",
"        22127708",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Navarra SV, Guzm&aacute;n RM, Gallacher AE, et al, \"Efficacy and Safety of Belimumab in Patients With Active Systemic Lupus Erythematosus: A Randomised, Placebo-Controlled, Phase 3 Trial,\"",
"      <i>",
"       Lancet",
"      </i>",
"      , 2011, 26(377):721-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/31/37365/abstract-text/21296403/pubmed\" id=\"21296403\" target=\"_blank\">",
"        21296403",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wallace DJ, Stohl W, Furie RA, et al, \"A Phase II, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of Belimumab in Patients With Active Systemic Lupus Erythematosus,\"",
"      <i>",
"       Arthritis Rheum",
"      </i>",
"      , 2009, 61(9):1168-78.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/31/37365/abstract-text/19714604/pubmed\" id=\"19714604\" target=\"_blank\">",
"        19714604",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16479 Version 25.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-201.211.0.116-77C6F20116-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_31_37365=[""].join("\n");
var outline_f36_31_37365=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14283838\">",
"      Special Alerts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12603131\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13243915\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12617225\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12617293\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12617294\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12617449\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12617450\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12618780\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12617223\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12617301\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12617284\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12617226\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12617259\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12617230\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12617231\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298821\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12757376\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12617227\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12617228\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12617229\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16257698\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16322894\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12617303\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13733205\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12617285\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12617287\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/16479\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/16479|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?19/48/20228?source=related_link\">",
"      Belimumab: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_31_37366="Small airway OSA MRI";
var content_f36_31_37366=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F74113%7EPULM%2F78076&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F74113%7EPULM%2F78076&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 611px\">",
"   <div class=\"ttl\">",
"    Reduced airway size in obstructive sleep apnea",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 591px; height: 236px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Comparison of an axial image at the minimum airway area (retropalatal region) of a normal subject (left) and a patient with sleep apnea (right). Note the smaller airway size and airway width in the patient with sleep apnea. In addition, the thickness of the lateral pharyngeal wall (distance between the airway and parapharyngeal fat pads) is larger in the patient with sleep apnea.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Richard J Schwab, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 472px\">",
"   <div class=\"ttl\">",
"    Reduced upper airway size in obstructive sleep apnea",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 452px; height: 213px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Comparison of a mid-sagittal image of a normal subject (left) and a patient with sleep apnea (right). Soft palate and tongue area are larger in the patient with sleep apnea, leading to a reduction in upper airway size.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Richard J Schwab, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_31_37366=[""].join("\n");
var outline_f36_31_37366=null;
var title_f36_31_37367="Sympathetic input to pupil";
var content_f36_31_37367=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F62879&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F62879&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Sympathetic pathway for pupillary innervation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 446px; height: 663px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Trigeminal ganglion.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Martin, TJ, Corbett, JJ. The Pupil. In: Neuro-ophthalmology: the requisites in ophthalmology, Krachmer, JH (Ed), Mosby, St. Louis 2000. Copyright &copy;2000 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_31_37367=[""].join("\n");
var outline_f36_31_37367=null;
var title_f36_31_37368="Mitoxantrone: Drug information";
var content_f36_31_37368=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Mitoxantrone: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?1/4/1094?source=see_link\">",
"    see \"Mitoxantrone: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?12/7/12407?source=see_link\">",
"    see \"Mitoxantrone: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5709094\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F197570\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Mitoxantrone Injection&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F197618\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antineoplastic Agent, Anthracenedione",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F197573\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Details concerning dosing in combination regimens should also be consulted.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       U.S. labeling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Acute nonlymphocytic leukemias (ANLL):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      Acute myeloid leukemia (AML) induction:",
"     </i>",
"     12 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     once daily for 3 days (in combination with cytarabine); for incomplete response, may repeat (7-10 days later) at 12 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     once daily for 2 days (in combination with cytarabine) (Arlin, 1990)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      AML consolidation",
"     </i>",
"     (beginning ~6 weeks after initiation of the final induction course): 12 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     once daily for 2 days (in combination with cytarabine), repeat in 4 weeks (Arlin, 1990)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Multiple sclerosis:",
"     </b>",
"     12 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     every 3 months (maximum lifetime cumulative dose: 140 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     ; discontinue use with LVEF &lt;50% or clinically significant reduction in LVEF)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Prostate cancer (advanced, hormone-refractory):",
"     </b>",
"     12-14 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     every 3 weeks (in combination with corticosteroids)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Canadian labeling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Acute nonlymphocytic leukemias (ANLL):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      AML induction:",
"     </i>",
"     10-12 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     once daily for 3 days (in combination with cytarabine); for incomplete response, may repeat at 10-12 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     once daily for 2 days (in combination with cytarabine)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      AML consolidation",
"     </i>",
"     (beginning ~6 weeks after initiation of the final induction course): 12 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     once daily for 2 days (in combination with cytarabine), repeat in 4 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Acute leukemias (relapsed):",
"     </b>",
"     Induction: 12 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     once daily for 5 consecutive days; may repeat once if needed (at the same dose and duration)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Breast cancer (metastatic), lymphoma:",
"     </b>",
"     Initial: Single agent: 14 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     every 21 days; reduce initial dose to &le;12 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     for myelosuppression due to previous treatment or for poor general health. When used in combination with other agents, reduce initial dose to 10-12 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Hepatocellular cancer:",
"     </b>",
"     Initial: Single agent: 14 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     every 21 days; reduce initial dose to &le;12 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     for myelosuppression due to previous treatment or for poor general health",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Adult unlabeled uses and/or dosing:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      AML, refractory:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      CLAG-M regimen:",
"     </i>",
"     10 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     once daily for 3 days (in combination with cladribine, cytarabine, and filgrastim), may repeat once if needed (Wierzbowska, 2008)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      MEC or EMA regimen:",
"     </i>",
"     6 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     once daily for 6 days (in combination with cytarabine and etoposide) (Amadori, 1991)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      Mitoxantrone/Etoposide:",
"     </i>",
"     10 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     once daily for 5 days (in combination with etoposide) (Ho, 1988)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      APL consolidation phase (second course):",
"     </b>",
"     10 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     once daily for 5 days (Sanz, 2004)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Hodgkin lymphoma, refractory:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      MINE-ESHAP regimen:",
"     </i>",
"     10 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     on day 1 every 28 days for up to 2 cycles (MINE is combination with mesna, ifosfamide, mitoxantrone, and etoposide; MINE alternates with ESHAP for up to 2 cycles of each) (Fernandez, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      VIM-D regimen:",
"     </i>",
"     10 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     on day 1 every 28 days (in combination with etoposide, ifosfamide, mesna, and dexamethasone) (Phillips, 1990)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Non-Hodgkin lymphoma (as part of combination chemotherapy regimens):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      CNOP regimen:",
"     </i>",
"     10 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     every 21 days (Bessell, 2003)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      FCMR regimen:",
"     </i>",
"     8 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     every 28 days (Forstpointner, 2004)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      FMR regimen:",
"     </i>",
"     10 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     every 21 days (Zinzani, 2004)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      FND regimen:",
"     </i>",
"     10 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     every 28 days (Tsimberidou, 2002)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      MINE-ESHAP regimen:",
"     </i>",
"     8 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     every 21 days for 6 cycles (MINE is combination with mesna, ifosfamide, mitoxantrone, and etoposide; followed by ESHAP) (Rodriguez, 1995)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Stem cell transplantation, autologous:",
"     </b>",
"     60 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     administered 4-5 days prior to autografting (as 3 divided doses over 1 hour each at 1-2 hour intervals on the same day; in combination with other chemotherapeutic agent[s]) (Oyan, 2006; Tarella, 2001)",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F197596\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?12/7/12407?source=see_link\">",
"      see \"Mitoxantrone: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Details concerning dosing in combination regimens should also be consulted.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Acute nonlymphocytic leukemias:",
"     </b>",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Acute myeloid leukemia (AML) consolidation phase (second course; unlabeled use):",
"     </i>",
"     10 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     once daily for 5 days (in combination with cytarabine) (Stevens, 1998)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Acute promyelocytic leukemia (APL) consolidation phase (second course; unlabeled use):",
"     </i>",
"     10 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     once daily for 5 days (Ortega, 2005; Sanz, 2004)",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F197574\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F3881589\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Safety and efficacy have not been established.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hemodialysis: Supplemental dose is not necessary",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Peritoneal dialysis: Supplemental dose is not necessary",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elderly: Clearance is decreased in elderly patients; use with caution",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F197575\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      <i>",
"       U.S. labeling:",
"      </i>",
"     </b>",
"     No dosage adjustment provided in the manufacturer&rsquo;s labeling; however, clearance is reduced in hepatic dysfunction. Patients with severe hepatic dysfunction (bilirubin &gt;3.4 mg/dL) have an AUC of 3 times greater than patients with normal hepatic function; consider dose adjustments.",
"     <b>",
"      Note:",
"     </b>",
"     MS patients with hepatic impairment should not receive mitoxantrone.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Canadian labeling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Mild-to-moderate impairment: No specific dosage adjustment provided; consider dose adjustments and monitor closely.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Severe impairment: Use is contraindicated.",
"    </p>",
"   </div>",
"   <div class=\"block dot drugH1Div\" id=\"F7289331\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adjustment for Toxicity",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      ANLL patients:",
"     </b>",
"     Severe or life-threatening nonhematologic toxicity: Withhold treatment until toxicity resolves",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      MS patients:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Neutrophils &lt;1500/mm",
"     <sup>",
"      3",
"     </sup>",
"     : Use is not recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Signs/symptoms of HF: Evaluate for cardiac signs/symptoms and LVEF.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     LVEF &lt;50% or baseline LVEF below the lower limit of normal (LLN): Use is not recommended.",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Canadian labeling (not in U.S. labeling):",
"      </i>",
"     </b>",
"     <b>",
"      Hepatocellular cancer, lymphoma, or breast cancer (metastatic):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     WBC nadir &gt;1500/mm",
"     <sup>",
"      3",
"     </sup>",
"     <b>",
"      and",
"     </b>",
"     platelet nadir &gt;50,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     and recovery &le;21 days: Repeat previous dose or increase dose by 2 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     if myelosuppression is inadequate.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     WBC nadir &gt;1500/mm",
"     <sup>",
"      3",
"     </sup>",
"     <b>",
"      and",
"     </b>",
"     platelet nadir &gt;50,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     and recovery &gt;21 days: Withhold treatment until recovery then resume at previous dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     WBC nadir &lt;1500/mm",
"     <sup>",
"      3",
"     </sup>",
"     <b>",
"      or",
"     </b>",
"     platelet nadir &lt;50,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     (regardless of recovery time): Withhold treatment until recovery then decrease previous dose by 2 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     WBC nadir &lt;1000/mm",
"     <sup>",
"      3",
"     </sup>",
"     <b>",
"      or",
"     </b>",
"     platelet nadir &lt;25,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     (regardless of recovery time): Withhold treatment until recovery then decrease previous dose by 4 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F197544\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution [concentrate, preservative free]: 2 mg/mL (10 mL, 12.5 mL, 15 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F197529\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F13934999\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM297876.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM297876.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F197547\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Irritant (is considered a vesicant by some institutions). For I.V. administration only; do not administer intrathecally, subcutaneously, intramuscularly or intra-arterially. Must be diluted prior to use. Avoid extravasation; may cause severe local tissue damage if extravasation occurs. Usually administered as a short I.V. infusion over 5-15 minutes; do not infuse over &lt;3-5 minutes.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     High doses for bone marrow transplant (unlabeled use) are usually given as 3 divided doses over 1 hour each at 1-2 hour intervals on the same day (Oyan, 2006; Tarella, 2001).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F197624\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     W, NS.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Allopurinol, amifostine, cladribine, etoposide, etoposide phosphate, filgrastim, fludarabine, gemcitabine, granisetron, linezolid, melphalan, ondansetron, oxaliplatin, sargramostim, teniposide, thiotepa, vinorelbine.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Amphotericin B cholesteryl sulfate complex, aztreonam, cefepime, doxorubicin liposome, pemetrexed, piperacillin/tazobactam, propofol.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Paclitaxel.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F197545\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Initial treatment of acute nonlymphocytic leukemias (ANLL [includes myelogenous, promyelocytic, monocytic and erythroid leukemias]); treatment of advanced hormone-refractory prostate cancer; secondary progressive or relapsing-remitting multiple sclerosis (MS)",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Canadian labeling: Additional uses (not in U.S. labeling): Treatment of metastatic breast cancer, relapsed leukemia (adults), lymphoma, and hepatocellular carcinoma",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F6215524\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of Hodgkin lymphoma (refractory), non-Hodgkin lymphomas (NHL), acute lymphocytic leukemia (ALL), relapsed acute myeloid leukemia (AML), breast cancer (metastatic), pediatric acute myelogenous leukemia (AML), pediatric acute promyelocytic leukemia (APL); part of a conditioning regimen for autologous hematopoietic stem cell transplantation (HSCT)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F197627\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       MitoXANtrone may be confused with methotrexate, mitoMYcin, mitotane, Mutamycin&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F197616\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Includes events reported with any indication; incidence varies based on treatment, dose, and/or concomitant medications",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Edema (10% to 30%), arrhythmia (3% to 18%), cardiac function changes (&le;18%), ECG changes (&le;11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Fever (6% to 78%), pain (8% to 41%), fatigue (&le;39%), headache (6% to 13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Alopecia (20% to 61%), nail bed changes (&le;11%), petechiae/bruising (6% to 11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Menstrual disorder (26% to 61%), amenorrhea (28% to 53%), hyperglycemia (10% to 31%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea (26% to 76%), vomiting (6% to 72%), diarrhea (14% to 47%), mucositis (10% to 29%; onset: &le;1 week), stomatitis (8% to 29%; onset: &le;1 week), anorexia (22% to 25%), weight gain/loss (13% to 17%), constipation (10% to 16%), GI bleeding (2% to 16%), abdominal pain (9% to 15%), dyspepsia (5% to 14%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Urinary tract infection (7% to 32%), abnormal urine (5% to 11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Neutropenia (79% to 100%; onset: &le;3 weeks; grade 4: 23% to 54%), leukopenia (9% to 100%), lymphopenia (72% to 95%), anemia/hemoglobin decreased (5% to 75%) thrombocytopenia (33% to 39%; grades 3/4: 3% to 4%), neutropenic fever (&le;11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: Alkaline phosphatase increased (&le;37%), transaminases increased (5% to 20%), GGT increased (3% to 15%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Weakness (&le;24%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Renal: BUN increased (&le;22%), creatinine increased (&le;13%), hematuria (&le;11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Upper respiratory tract infection (7% to 53%), pharyngitis (&le;19%), dyspnea (6% to 18%), cough (5% to 13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Infection (4% to 60%), sepsis (ANLL 31% to 34%), fungal infection (9% to 15%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: CHF (&le;5%), ischemia (&le;5%), LVEF decreased (&le;5%), hypertension (&le;4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Chills (&le;5%), anxiety (5%), depression (5%), seizure (2% to 4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Cutaneous mycosis (&le;10%), skin infection (&le;5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hypocalcemia (10%), hypokalemia (7% to 10%), hyponatremia (9%), menorrhagia (7%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal:  Aphthosis (&le;10%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Impotence (&le;7%), sterility (&le;5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Granulocytopenia (6%), hemorrhage (5% to 6%), secondary acute leukemias (&le;3%; includes AML, APL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: Jaundice (3% to 7%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Back pain (6% to 8%), myalgia (&le;5%), arthralgia (&le;5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Conjunctivitis (&le;5%), blurred vision (&le;3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Renal: Renal failure (&le;8%), proteinuria (&le;6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Rhinitis (10%), pneumonia (&le;9%), sinusitis (&le;6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Systemic infection (&le;10%), diaphoresis (&le;9%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Allergic reaction, anaphylactoid reactions, anaphylaxis, chest pain, dehydration; extravasation at injection site (may result in burning, erythema, pain, skin discoloration, swelling, or tissue necrosis); interstitial pneumonitis (with combination chemotherapy), hyperuricemia, hypotension, phlebitis at the infusion site, rash, sclera discoloration (blue), tachycardia, urine discoloration (blue-green), urticaria",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F197550\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to mitoxantrone or any component of the formulation",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Canadian labeling: Additional contraindications (not in U.S. labeling): Prior hypersensitivity to anthracyclines; prior substantial anthracycline exposure and abnormal cardiac function prior to initiation of mitoxantrone therapy; presence of severe myelosuppression due to prior chemo- and/or radiotherapy; severe hepatic impairment; intrathecal administration",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F197533\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bone marrow suppression: Treatment may lead to severe myelosuppression; unless the expected benefit outweighs the risk, use is generally not recommended in patients with pre-existing myelosuppression from prior chemotherapy.",
"     <b>",
"      [U.S. Boxed Warning]: Usually should not be administered if baseline neutrophil count &lt;1500 cells/mm",
"      <sup>",
"       3",
"      </sup>",
"      (except for in the treatment of ANLL). Monitor blood counts and monitor for infection due to neutropenia.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hyperuricemia: Rapid lysis of tumor cells may lead to hyperuricemia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Myocardial toxicity:",
"     <b>",
"      [U.S. Boxed Warning]: May cause myocardial toxicity and potentially-fatal heart failure (HF); risk increases with cumulative dosing. Effects may occur during therapy or may be delayed (months or years after completion of therapy). Predisposing factors for mitoxantrone-induced cardiotoxicity include prior anthracycline or anthracenedione therapy, prior cardiovascular disease, concomitant use of cardiotoxic drugs, and mediastinal/pericardial irradiation, although may also occur in patients without risk factors. Prior to therapy initiation, evaluate all patients for cardiac-related signs/symptoms, including history, physical exam, and ECG; and evaluate baseline left ventricular ejection fraction (LVEF) with echocardiogram or multigated radionuclide angiography (MUGA) or MRI. Not recommended for use in MS patients when LVEF &lt;50%, or baseline LVEF below the lower limit of normal (LLN). Evaluate for cardiac signs/symptoms (by history, physical exam, and ECG) and evaluate LVEF (using same method as baseline LVEF) in MS patients prior to each dose and if signs/symptoms of HF develop. Use in MS should be limited to a cumulative dose of &le;140 mg/m",
"      <sup>",
"       2",
"      </sup>",
"      , and discontinued if LVEF falls below LLN or a significant decrease in LVEF is observed; decreases in LVEF and HF have been observed in patients with MS who have received cumulative doses &lt;100 mg/m",
"      <sup>",
"       2",
"      </sup>",
"      . Patients with MS should undergo annual LVEF evaluation following discontinuation of therapy to monitor for delayed cardiotoxicity.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Secondary malignancy:",
"     <b>",
"      [U.S. Boxed Warning]: Treatment with mitoxantrone increases the risk of developing secondary acute myelogenous leukemia (AML) in patients with cancer and in patients with MS;",
"     </b>",
"     acute promyelocytic leukemia (APL) has also been observed. Symptoms of acute leukemia include excessive bruising, bleeding and recurrent infections. The risk for secondary leukemia is increased in patients who are heavily pretreated, with higher doses, and with combination chemotherapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Clearance is reduced in patients with hepatic impairment; use with caution; dosage adjustment recommended. Not for treatment of multiple sclerosis in patients with concurrent hepatic impairment. Canadian labeling contraindicates use in severe impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Multiple sclerosis: Not for treatment of primary progressive multiple sclerosis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate administration:",
"     <b>",
"      [U.S. Boxed Warning]: For I.V. administration only, into a free-flowing I.V.; may cause severe local tissue damage if extravasation occurs; do not administer subcutaneously, intramuscularly, or intra-arterially. Do not administer intrathecally; may cause serious and permanent neurologic damage.",
"     </b>",
"     Extravasation resulting in burning, erythema, pain, swelling and skin discoloration (blue) has been reported; extravasation may result in tissue necrosis and require debridement for skin graft.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Blue-green coloration: May cause urine, saliva, tears, and sweat to turn blue-green for 24 hours postinfusion; whites of eyes may have blue-green tinge.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Experienced physician:",
"     <b>",
"      [U.S. Boxed Warning]: Should be administered under the supervision of a physician experienced in cancer chemotherapy agents.",
"     </b>",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F197613\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP3A4 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F197538\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Immunosuppressants may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for agranulocytosis may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Coccidioidin Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioidin Skin Test.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Echinacea: May diminish the therapeutic effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Limit the maximum adult dose of lomitapide to 30 mg daily when used in combination with any weak CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or other non-disease modifying antirheumatic drugs (non-DMARDs) is permitted, and this warning seems to particularly focused on more potent immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Vaccinial infections may develop. Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F197565\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Herb/Nutraceutical: Avoid echinacea (may diminish the immunosuppressant effect).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F197540\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F197553\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse effects were noted in animal reproduction studies. May cause fetal harm if administered to a pregnant woman. Pregnancy should be avoided while on treatment. Women with multiple sclerosis who are of reproductive potential should have a pregnancy test prior to each dose.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F197584\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F197554\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Mitoxantrone is excreted in human milk and significant concentrations (18 ng/mL) have been reported for 28 days after the last administration. Because of the potential for serious adverse reactions in infants from mitoxantrone, breast-feeding should be discontinued before starting treatment.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323431\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Concentrate",
"     </b>",
"     (Mitoxantrone HCl Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20 mg/10 mL (10 mL): $303.53",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25 mg/12.5 mL (12.5 mL): $324.71",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     30 mg/15 mL (15 mL): $409.42",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F197542\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     CBC with differential, serum uric acid (for leukemia treatment), liver function tests; for the treatment of multiple sclerosis, obtain pregnancy test; monitor injection site for extravasation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     <i>",
"      Cardiac monitoring:",
"     </i>",
"     Prior to initiation, evaluate all patients for cardiac-related signs/symptoms, including history, physical exam, and ECG; evaluate baseline and periodic left ventricular ejection fraction (LVEF) with echocardiogram or multigated radionuclide angiography (MUGA) or MRI. In patients with MS, evaluate for cardiac signs/symptoms (by history, physical exam, and ECG) and evaluate LVEF (using same method as baseline LVEF) prior to each dose and if signs/symptoms of HF develop. Patients with MS should undergo annual LVEF evaluation following discontinuation of therapy to monitor for delayed cardiotoxicity.",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F197555\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Bluxantron (EC);",
"     </li>",
"     <li>",
"      Domitrone (PH);",
"     </li>",
"     <li>",
"      Ebexantron (SG);",
"     </li>",
"     <li>",
"      Elsep (FR);",
"     </li>",
"     <li>",
"      Heng En (CL);",
"     </li>",
"     <li>",
"      Mi Xi Ning (CL);",
"     </li>",
"     <li>",
"      Misostol (PY, VE);",
"     </li>",
"     <li>",
"      Mitoxgen (AR, MX);",
"     </li>",
"     <li>",
"      Mitroxone (MX);",
"     </li>",
"     <li>",
"      Mittrone (KP);",
"     </li>",
"     <li>",
"      Neotalem (CN, TH);",
"     </li>",
"     <li>",
"      Novantron (AT, CH, DE);",
"     </li>",
"     <li>",
"      Novantrone (BE, BR, CL, DK, ES, FI, FR, GB, GR, HN, HR, HU, IL, IT, JP, LU, NL, NO, NZ, PK, PL, PT, RU, SE, TR, TW);",
"     </li>",
"     <li>",
"      Oncotron (IN);",
"     </li>",
"     <li>",
"      Oncotrone (BG);",
"     </li>",
"     <li>",
"      Onkotrone (AU, EE, HU, NZ);",
"     </li>",
"     <li>",
"      Pralifan (ES);",
"     </li>",
"     <li>",
"      Refador (CZ);",
"     </li>",
"     <li>",
"      Santrone (HK)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F197532\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Related to the anthracyclines, mitoxantrone intercalates into DNA resulting in cross-links and strand breaks; binds to nucleic acids and inhibits DNA and RNA synthesis by template disordering and steric obstruction; replication is decreased by binding to DNA topoisomerase II and seems to inhibit the incorporation of uridine into RNA and thymidine into DNA; active throughout entire cell cycle (cell-cycle nonspecific)",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F197549\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral: Poor",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 14 L/kg; V",
"     <sub>",
"      dss",
"     </sub>",
"     : &gt;1000 L/m",
"     <sup>",
"      2",
"     </sup>",
"     ; distributes extensively into tissue (pleural fluid, kidney, thyroid, liver, heart) and red blood cells",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 78%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic; pathway not determined",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Terminal: 23-215 hours (median: ~75 hours); may be prolonged with hepatic impairment",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Feces (25%); urine (6% to 11%; 65% as unchanged drug)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Amadori S, Arcese W, Isacchi G, et al, &ldquo;Mitoxantrone, Etoposide, and Intermediate-Dose Cytarabine: An Effective and Tolerable Regimen for the Treatment of Refractory Acute Myeloid Leukemia,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 1991, 9(7):1210-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/31/37368/abstract-text/2045861/pubmed\" id=\"2045861\" target=\"_blank\">",
"        2045861",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Arlin Z, Case DC Jr, Moore J, et al, &ldquo;Randomized Multicenter Trial of Cytosine Arabinoside With Mitoxantrone or Daunorubicin in Previously Untreated Adult Patients With Acute Nonlymphocytic Leukemia (ANLL). Lederle Cooperative Group,&rdquo;",
"      <i>",
"       Leukemia",
"      </i>",
"      , 1990, 4(3):177-83.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/31/37368/abstract-text/2179638/pubmed\" id=\"2179638\" target=\"_blank\">",
"        2179638",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bessell EM, Burton A, Haynes AP, et al, &ldquo;A Randomised Multicentre Trial of Modified CHOP Versus MCOP in Patients Aged 65 Years and Over With Aggressive Non-Hodgkin's Lymphoma,",
"      <i>",
"       Ann Oncol",
"      </i>",
"      , 2003, 14(2):258-67.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/31/37368/abstract-text/12562653/pubmed\" id=\"12562653\" target=\"_blank\">",
"        12562653",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Donelli MG,  Zuchetti M, Munzone E, et al, &ldquo;Pharmacokinetics of Anticancer Agents in Patients With Impaired Liver Function,&rdquo;",
"      <i>",
"       Eur J Cancer,",
"      </i>",
"      1998, 34(1):33-46.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/31/37368/abstract-text/9624235/pubmed\" id=\"9624235\" target=\"_blank\">",
"        9624235",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ehninger G, Schuler U, Proksch B, et al, \"Pharmacokinetics and Metabolism of Mitoxantrone. A Review,\"",
"      <i>",
"       Clin Pharmacokinet",
"      </i>",
"      , 1990, 18(5):365-80.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/31/37368/abstract-text/2185907/pubmed\" id=\"2185907\" target=\"_blank\">",
"        2185907",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Faulds D, Balfour JA, Chrisp P, et al, &ldquo;Mitoxantrone. A Review of Its Pharmacodynamic and Pharmacokinetic Properties, and Therapeutic Potential in the Chemotherapy of Cancer,&rdquo;",
"      <i>",
"       Drugs",
"      </i>",
"      , 1991, 41(3):400-49.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/31/37368/abstract-text/1711446/pubmed\" id=\"1711446\" target=\"_blank\">",
"        1711446",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fernandex de Larrea C, Martinez C, Gaya A, et al, &ldquo;Salvage Chemotherapy With Alternating MINE-ESHAP Regimen in Relapsed or Refractory Hodgkin&rsquo;s Lymphoma Followed By Autologous Stem-Cell Transplantation,&rdquo;",
"      <i>",
"       Ann Oncol",
"      </i>",
"      , 2010, 21(6):1211-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/31/37368/abstract-text/19889622/pubmed\" id=\"19889622\" target=\"_blank\">",
"        19889622",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Forstpointner R, Dreyling M, Repp R, et al, &ldquo;The Addition of Rituximab to a Combination of Fludarabine, Cyclophosphamide, Mitoxantrone (FCM) Significantly Increases the Response Rate and Prolongs Survival as Compared With FCM Alone in Patients With Relapsed and Refractory Follicular and Mantle Cell Lymphomas: Results of a Prospective Randomized Study of the German Low-Grade Lymphoma Study Group,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2004, 104(10):3064-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/31/37368/abstract-text/15284112/pubmed\" id=\"15284112\" target=\"_blank\">",
"        15284112",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Henderson IC, Allegra JC, Woodcock T, et al, &ldquo;Randomized Clinical Trial Comparing Mitoxantrone With Doxorubicin in Previously Treated Patients With Metastatic Breast Cancer,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 1989, 7(5):560-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/31/37368/abstract-text/2468745/pubmed\" id=\"2468745\" target=\"_blank\">",
"        2468745",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ho AD, Lipp T, Ehninger G, et al, &ldquo;Combination of Mitoxantrone and Etoposide in Refractory Acute Myelogenous Leukemia an Active and Well-Tolerated Regimen,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 1988, 6(2):213-17.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/31/37368/abstract-text/3422260 /pubmed\" id=\"3422260 \" target=\"_blank\">",
"        3422260",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jeffrey LP, Chairman, National Study Commission on Cytotoxic Exposure. Position Statement. &ldquo;The Handling of Cytotoxic Agents by Women Who Are Pregnant, Attempting to Conceive, or Breast-Feeding,&rdquo; January 12, 1987.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mandelli F, Vignetti M, Suciu S, et al, &ldquo;Daunorubicin versus Mitoxantrone versus Idarubicin as Induction and Consolidation Chemotherapy for Adults With Acute Myeloid Leukemia: The EORTC and GIMEMA Groups Study AML-10,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2009, 27(32):5397-403.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/31/37368/abstract-text/19826132/pubmed\" id=\"19826132\" target=\"_blank\">",
"        19826132",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ortega JJ, Madero L, Martin G, et al, &ldquo;Treatment With All-",
"      <i>",
"       Trans",
"      </i>",
"      Retinoic Acid and Anthracycline Monochemotherapy for Children With Acute Promyelocytic Leukemia: A Multicenter Study by the PETHEMA Group,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2005, 23(30):7632-40.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/31/37368/abstract-text/16234524/pubmed\" id=\"16234524\" target=\"_blank\">",
"        16234524",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Oyan B, Koc Y, Ozdemir E, et al, &ldquo;High Dose Sequential Chemotherapy and Autologous Stem Cell Transplantation in Patients With Relapsed/Refractory Lymphoma,&rdquo;",
"      <i>",
"       Leuk Lymphoma",
"      </i>",
"      , 2006, 47(8):1545-52.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/31/37368/abstract-text/16966265/pubmed\" id=\"16966265\" target=\"_blank\">",
"        16966265",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      P&eacute;rez Fidalgo JA, Garc&iacute;a Fabregat L, Cervantes A, et al, &ldquo;Management of Chemotherapy Extravasation: ESMO-EONS Clinical Practice Guidelines,&rdquo;",
"      <i>",
"       Ann Oncol",
"      </i>",
"      , 2012, 23(Suppl 7):167-73.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/31/37368/abstract-text/22997449/pubmed\" id=\"22997449\" target=\"_blank\">",
"        22997449",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Petrylak DP, Tangen CM, Hussain MH, et al, &ldquo;Docetaxel and Estramustine Compared With Mitoxantrone and Prednisone for Advanced Refractory Prostate Cancer,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2004, 351(15):1513-20.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/31/37368/abstract-text/15470214/pubmed\" id=\"15470214\" target=\"_blank\">",
"        15470214",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Phillips JK, Spearing RL, Davies JM, et al, &ldquo;VIM-D Salvage Chemotherapy in Hodgkin's Disease,&rdquo;",
"      <i>",
"       Cancer Chemother Pharmacol",
"      </i>",
"      , 1990, 27(2):161-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/31/37368/abstract-text/2249334/pubmed\" id=\"2249334\" target=\"_blank\">",
"        2249334",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pratt CB, Vietti TJ, Etcubanas E, et al, &ldquo;Novantrone&reg; for Childhood Malignant Solid Tumors. A Pediatric Oncology Group Phase II Study,&rdquo;",
"      <i>",
"       Invest New Drugs",
"      </i>",
"      , 1986, 4(1):43-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/31/37368/abstract-text/3700039/pubmed\" id=\"3700039\" target=\"_blank\">",
"        3700039",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rodriguez MA, Cabanillas FC, Velasquez W, et al, &ldquo;Results of a Salvage Treatment Program for Relapsing Lymphoma: MINE Consolidated With ESHAP,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 1995, 13(7):1734-41.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/31/37368/abstract-text/602363/pubmed\" id=\"602363\" target=\"_blank\">",
"        602363",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sanz MA, Martin G, Gonzalez M, et al, &ldquo;Risk-Adapted Treatment of Acute Promyelocytic Leukemia With All-",
"      <i>",
"       Trans",
"      </i>",
"      -Retinoic Acid and Anthracycline Monochemotherapy: A Multicenter Study by the PETHEMA Group,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2004, 103(4):1237-43.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/31/37368/abstract-text/14576047/pubmed\" id=\"14576047\" target=\"_blank\">",
"        14576047",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Scott LJ and Figgitt DP, \"Mitoxantrone: A Review of its Use in Multiple Sclerosis,\"",
"      <i>",
"       CNS Drugs",
"      </i>",
"      , 2004, 18(6):379-96.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/31/37368/abstract-text/15089110/pubmed\" id=\"15089110\" target=\"_blank\">",
"        15089110",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Stevens RF, Hann IM, Wheatley K, et al, &ldquo;Marked Improvements in Outcome With Chemotherapy Alone in Paediatric Acute Myeloid Leukemia: Results of the United Kingdom Medical Research Council's 10th AML Trial: MRC Childhood Leukaemia Working Party,&rdquo;",
"      <i>",
"       Br J Haematol",
"      </i>",
"      , 1998, 101(1):130-40.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/31/37368/abstract-text/9576193/pubmed\" id=\"9576193\" target=\"_blank\">",
"        9576193",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tannock IF, de Wit R, Berry WR, et al, &ldquo;Docetaxel Plus Prednisone or Mitoxantrone Plus Prednisone for Advanced Prostate Cancer,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2004, 351(15):1502-12.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/31/37368/abstract-text/15470213/pubmed\" id=\"15470213\" target=\"_blank\">",
"        15470213",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tarella C, Zallio F, Caracciolo D, et al, &ldquo;High-Dose Mitoxantrone + Melphalan (MITO/L-PAM) as Conditioning Regimen Supported by Peripheral Blood Progenitor Cell (PBPC) Autograft in 113 Lymphoma Patients: High Tolerability With Reversible Cardiotoxicity,&rdquo;",
"      <i>",
"       Leukemia",
"      </i>",
"      , 2001, 15(2):256-63.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/31/37368/abstract-text/11236941/pubmed\" id=\"11236941\" target=\"_blank\">",
"        11236941",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Toledano A, Azria D, Garaud P, et al, &ldquo;Phase III Trial of Concurrent or Sequential Adjuvant Chemoradiotherapy After Conservative Surgery for Early-Stage Breast Cancer: Final Results of the ARCOSEIN Trial,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2007, 25(4):405-10.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/31/37368/abstract-text/17264336/pubmed\" id=\"17264336\" target=\"_blank\">",
"        17264336",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tsimberidou AM, McLaughlin P, Younes A, et al, &ldquo;Fludarabine, Mitoxantrone, Dexamethasone (FND) Compared With an Alternating Triple Therapy (ATT) Regimen in Patients With Stage IV Indolent Lymphoma,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2002, 100(13):4351-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/31/37368/abstract-text/12393618/pubmed\" id=\"12393618\" target=\"_blank\">",
"        12393618",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Vitolo U, Chiappella A, Angelucci E, et al, &ldquo;Dose-Dense and High-Dose Chemotherapy Plus Rituximab With Autologous Stem Cell Transplantation for Primary Treatment of Diffuse Large B-Cell Lymphoma With a Poor Prognosis: A Phase II Multicenter Study,&rdquo;",
"      <i>",
"       Haematologica",
"      </i>",
"      , 2009, 94(9):1250-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/31/37368/abstract-text/19586937/pubmed\" id=\"19586937\" target=\"_blank\">",
"        19586937",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Weiss M, Maslak P, Feldman E, et al, &ldquo;Cytarabine With High-Dose Mitoxantrone Induces Rapid Complete Remissions in Adult Acute Lymphoblastic Leukemia Without the Use of Vincristine or Prednisone,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 1996, 14(9):2480-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/31/37368/abstract-text/8823326/pubmed\" id=\"8823326\" target=\"_blank\">",
"        8823326",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wierzbowska A, Robak T, Pluta A, et al, &ldquo;Cladribine Combined With High Doses of Arabinoside Cytosine, Mitoxantrone, and G-CSF (CLAG-M) is a Highly Effective Salvage Regimen in Patients With Refractory and Relapsed Acute Myeloid Leukemia of the Poor Risk: A Final Report of the Polish Adult Leukemia Group,&rdquo;",
"      <i>",
"       Eur J Haematol",
"      </i>",
"      2008; 80(2):115-26.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/31/37368/abstract-text/18076637/pubmed\" id=\"18076637\" target=\"_blank\">",
"        18076637",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Zinzani PL, Pulsoni A, Perrotti A, et al, &ldquo;Fludarabine Plus Mitoxantrone With and Without Rituximab Versus CHOP With and Without Rituximab as Front-Line Treatment for Patients With Follicular Lymphoma,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2004, 22(13):2654-61.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/31/37368/abstract-text/15159414/pubmed\" id=\"15159414\" target=\"_blank\">",
"        15159414",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Zinzani PL, Tani M, Pulsoni A, et al, &ldquo;Fludarabine and Mitoxantrone Followed by Yttrium-90 Ibritumomab Tiuxetan in Previously Untreated Patients With Follicular Non-Hodgkin Lymphoma Trial: A Phase II Non-Randomised Trial (FLUMIZ),&rdquo;",
"      <i>",
"       Lancet Oncol",
"      </i>",
"      , 2008, 9(4):352-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/31/37368/abstract-text/18342572/pubmed\" id=\"18342572\" target=\"_blank\">",
"        18342572",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9660 Version 41.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.248-3548BCC041-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_31_37368=[""].join("\n");
var outline_f36_31_37368=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5709094\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F197570\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F197618\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F197573\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F197596\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F197574\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3881589\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F197575\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7289331\">",
"      Dosing: Adjustment for Toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F197544\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F197529\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13934999\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F197547\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F197624\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F197545\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6215524\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F197627\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F197616\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F197550\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F197533\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F197613\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F197538\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F197565\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F197540\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F197553\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F197584\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F197554\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323431\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F197542\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F197555\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F197532\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F197549\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9660\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9660|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?1/4/1094?source=related_link\">",
"      Mitoxantrone: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?12/7/12407?source=related_link\">",
"      Mitoxantrone: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_31_37369="Selecting a reperfusion strategy for acute ST elevation myocardial infarction";
var content_f36_31_37369=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Selecting a reperfusion strategy for acute ST elevation myocardial infarction",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/31/37369/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/31/37369/contributors\">",
"     C Michael Gibson, MS, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/31/37369/contributors\">",
"     Duane S Pinto, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/31/37369/contributors\">",
"     Donald Cutlip, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/31/37369/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/31/37369/contributors\">",
"     Christopher P Cannon, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/31/37369/contributors\">",
"     Bernard J Gersh, MB, ChB, DPhil, FRCP, MACC",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/31/37369/contributors\">",
"     James Hoekstra, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/31/37369/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/31/37369/contributors\">",
"     Gordon M Saperia, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?36/31/37369/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 13, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Coronary artery reperfusion with either primary percutaneous coronary intervention (PCI) or fibrinolytic therapy, if performed in a timely manner, improves clinical outcomes compared to no reperfusion in nearly all groups of patients with an acute ST elevation myocardial infarction (STEMI). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/46/16106?source=see_link&amp;anchor=H4#H4\">",
"     \"Primary percutaneous coronary intervention in acute ST elevation myocardial infarction: Determinants of outcome\", section on 'Time from hospital arrival (door-to-balloon time) on outcomes'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/43/1721?source=see_link&amp;anchor=H69239847#H69239847\">",
"     \"Fibrinolytic therapy in acute ST elevation myocardial infarction: Initiation of therapy\", section on 'Timing'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Occasionally a decision to not attempt to reperfuse the patient will be made due to reasons such as serious comorbidities, end of life issues, or late presentation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/43/1721?source=see_link&amp;anchor=H2#H2\">",
"     \"Fibrinolytic therapy in acute ST elevation myocardial infarction: Initiation of therapy\", section on 'Indications'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/46/16106?source=see_link&amp;anchor=H1#H1\">",
"     \"Primary percutaneous coronary intervention in acute ST elevation myocardial infarction: Determinants of outcome\", section on 'Introduction'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Primary PCI, if performed in a timely fashion, is the reperfusion therapy of choice in most patients with STEMI, including an MI with new or presumably new left bundle branch block, or a true posterior MI. However, not all facilities have the ability to perform primary PCI in a timely manner, and for many patients a decision must be made between the local administration of fibrinolytic therapy or transfer to a nearby institution for primary PCI.",
"   </p>",
"   <p>",
"    The factors that must be considered before choosing one of these two reperfusion strategies in patients with STEMI will be reviewed here. The clinical-trial data supporting these conclusions, the clinical use of both primary PCI and fibrinolytic therapy, and the role of PCI after fibrinolytic are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/16/29961?source=see_link\">",
"     \"Primary percutaneous coronary intervention versus fibrinolysis in acute ST elevation myocardial infarction: Clinical trials\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/46/16106?source=see_link\">",
"     \"Primary percutaneous coronary intervention in acute ST elevation myocardial infarction: Determinants of outcome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/43/1721?source=see_link\">",
"     \"Fibrinolytic therapy in acute ST elevation myocardial infarction: Initiation of therapy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/42/34473?source=see_link\">",
"     \"Percutaneous coronary intervention after fibrinolysis for acute ST elevation myocardial infarction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/14/25830?source=see_link\">",
"     \"Prehospital fibrinolysis (thrombolysis) for suspected acute ST elevation myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Our recommendations found at the end of this topic are in broad agreement with guidelines from the American College of Cardiology",
"    <span class=\"nowrap\">",
"     Foundation/American",
"    </span>",
"    Heart Association",
"    <span class=\"nowrap\">",
"     (ACCF/AHA)",
"    </span>",
"    and the European Society of Cardiology (ESC) on STEMI and PCI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/31/37369/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. These guidelines recommended that patients with acute STEMI who present within 12 hours of symptom onset be treated with immediate reperfusion therapy.",
"   </p>",
"   <p>",
"    Immediate reperfusion is not as urgent in patients with a non-ST elevation MI in whom a completely occluded infarct-related artery at presentation is much less common. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/1/29722?source=see_link\">",
"     \"Coronary arteriography and revascularization for unstable angina or non-ST elevation acute myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GENERAL ISSUES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prompt restoration of normal blood flow in the infarct-related artery is essential to myocardial salvage and mortality reduction in patients with STEMI (",
"    <a class=\"graphic graphic_figure graphicRef75629 \" href=\"mobipreview.htm?15/40/16013\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/31/37369/abstract/4\">",
"     4",
"    </a>",
"    ]. This relationship is particularly important in the first few hours after symptom onset, when the amount of myocardium salvageable by reperfusion is greatest (",
"    <a class=\"graphic graphic_figure graphicRef53374 \" href=\"mobipreview.htm?30/18/31021\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/31/37369/abstract/5-7\">",
"     5-7",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Time from symptom onset'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    As the benefits of reperfusion with either primary PCI or fibrinolysis decline rapidly with time, a treatment strategy with either primary PCI or fibrinolytic therapy should be chosen and implemented as soon as possible [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/31/37369/abstract/8\">",
"     8",
"    </a>",
"    ]. Based upon data from randomized trials, primary PCI is preferred when performed in a timely fashion by an expert operator [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/31/37369/abstract/8-11\">",
"     8-11",
"    </a>",
"    ]. However, when a patient presents to a facility that does not have primary PCI capability, or when it is not available, the choice between primary PCI and fibrinolytic therapy can be complicated, primarily for those patients who present within three hours of symptom onset (see",
"    <a class=\"local\" href=\"#H12\">",
"     'PCI-related delay'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    Studies of successful hospitals have identified a number of organizational changes that contributed to minimizing treatment delay, two of which were performance of prehospital electrocardiograms to activate the catheterization laboratory and substantial interdisciplinary collaboration in the establishment of STEMI care protocols and continuous quality assurance. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/46/16106?source=see_link&amp;anchor=H5#H5\">",
"     \"Primary percutaneous coronary intervention in acute ST elevation myocardial infarction: Determinants of outcome\", section on 'Hospital performance'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Due to the critical relationship between time-to-reperfusion and mortality reduction, this decision should be made rapidly, guided by a predetermined, institution-specific, written protocol. These protocols should be designed and customized for each institution because important predictors of outcome, including the experience of operators and the ease and speed of patient transfer, are unique to each hospital. Such protocols facilitate the delivery of standardized evidence-based care and minimize delays in implementing reperfusion therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/31/37369/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H334599427\">",
"    <span class=\"h1\">",
"     FACTORS DETERMINING CHOICE OF REPERFUSION STRATEGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;If timely, high-quality primary PCI is available, it is the preferred reperfusion strategy for most patients with STEMI. It is presumed that the procedure will be done expeditiously (door-to-balloon time less than 90 minutes). These issues are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/16/29961?source=see_link&amp;anchor=H3#H3\">",
"     \"Primary percutaneous coronary intervention versus fibrinolysis in acute ST elevation myocardial infarction: Clinical trials\", section on 'Primary PCI versus fibrinolytic trials'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/46/16106?source=see_link&amp;anchor=H269831116#H269831116\">",
"     \"Primary percutaneous coronary intervention in acute ST elevation myocardial infarction: Determinants of outcome\", section on 'Early versus late presentation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/46/16106?source=see_link&amp;anchor=H15#H15\">",
"     \"Primary percutaneous coronary intervention in acute ST elevation myocardial infarction: Determinants of outcome\", section on 'Importance of local expertise'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, there are circumstances when reperfusion with fibrinolytic therapy is a reasonable alternative. The following section discusses factors that should go into decision making regarding reperfusion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/31/37369/abstract/13-15\">",
"     13-15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     PCI-related delay",
"    </span>",
"    &nbsp;&mdash;&nbsp;Outcomes for both fibrinolytic therapy and primary PCI worsen as the time to treatment with either therapy increases. Similarly, as the PCI related delay (defined below) increases, the benefit from primary PCI compared to fibrinolytic therapy declines. The following terminology is used when evaluating time to treatment:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The door-to-needle time refers to the time from presentation at a hospital (or ambulance) to the administration of fibrinolytic therapy.",
"     </li>",
"     <li>",
"      The door-to-balloon time refers to the time from presentation at a PCI center to first balloon inflation. The trial data demonstrating the importance of the door-to-balloon time on patient outcome are discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?15/46/16106?source=see_link&amp;anchor=H4#H4\">",
"       \"Primary percutaneous coronary intervention in acute ST elevation myocardial infarction: Determinants of outcome\", section on 'Time from hospital arrival (door-to-balloon time) on outcomes'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The PCI-related delay is the difference between the door-to-balloon time and the door-to-needle time. The PCI-related delay overestimates the reperfusion delay for PCI somewhat, since PCI reperfusion is immediate while fibrinolytic therapy generally does not reestablish perfusion for about 30 minutes.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The impact of PCI-related delay on survival comes from both randomized trials and observational studies. In a 2003 review of 23 randomized trials of primary PCI versus fibrinolysis, which enrolled a total of 7739 patients, the magnitude of the survival benefit at four to six weeks declined as the mean PCI-related delay increased. When the PCI-related delay was more than 62 minutes there was no survival advantage to primary PCI over fibrinolysis (",
"    <a class=\"graphic graphic_figure graphicRef67756 \" href=\"mobipreview.htm?8/37/8798\">",
"     figure 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/31/37369/abstract/16\">",
"     16",
"    </a>",
"    ]. In 13 trials evaluating the combined endpoint of death, reinfarction, or stroke at four to six weeks (4946 patients), every additional 10 minute delay in door-to-balloon time beyond the door-to-needle time reduced the absolute benefit of primary PCI by 1.17 percent. The two strategies became equivalent with regard to the combined endpoint after a delay of 93 minutes (",
"    <a class=\"graphic graphic_figure graphicRef80787 \" href=\"mobipreview.htm?9/33/9758\">",
"     figure 4",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    However, in the community, door-to-balloon times and PCI-related delays are significantly longer than those in randomized clinical trials. In a 2012 study of patients enrolled in the United States National Registry of Myocardial Infarction (NRMI) -2,3, 4 and 5 (1994 to 2006) registries, the median door-to-balloon time was 161 minutes, compared to a median of 90 to 107 minutes for patients enrolled in randomized clinical trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/31/37369/abstract/17-19\">",
"     17-19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Increasing PCI-related delay also worsens outcomes in patients not enrolled in clinical trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/31/37369/abstract/17,20\">",
"     17,20",
"    </a>",
"    ]. The following findings were noted in a 2011 report of over 19,000 propensity-score matched patients enrolled in the NRMI 2, 3, 4, and 5 registries [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/31/37369/abstract/20\">",
"     20",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among patients who were transferred for primary PCI, delays of &gt;90 minutes were seen in 68 percent of cases and the median door to balloon time was 161 minutes (the median door to needle time was 35 minutes).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Multivariable analysis found no mortality advantage for primary PCI over fibrinolysis in patients with a PCI related delay longer than approximately 120 minutes. For those groups of patients with PCI delay of &lt;60 and 60 to 90 minutes, the in-hospital death rates favored PCI (2.7 versus 7.4 and 3.6 versus 5.5 percent, respectively), whereas the rates were similar for the group of patients with PCI delay of &gt;90 minutes (5.7 versus 6.1 percent, respectively).",
"   </p>",
"   <p>",
"    Interpretation of the results of these studies should consider the following issues:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There may be confounding factors associated with both increased PCI-related delay and worse outcomes (in the observational studies), such as the experience of hospitals and operators in the relevant studies.",
"     </li>",
"     <li>",
"      When endpoints in addition to survival (eg, reinfarction and stroke) are considered, the advantage of primary PCI over fibrinolysis may be retained with slightly greater PCI-related delay [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/31/37369/abstract/20\">",
"       20",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In stratified analyses based upon patient age, duration of symptoms, and infarct location, the PCI-related delay at which mortality rates with primary PCI were no better than that of fibrinolysis varied considerably depending on patient age, symptom duration, and infarct location [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/31/37369/abstract/20\">",
"       20",
"      </a>",
"      ]. This point is discussed in detail in the next section.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H334596199\">",
"    <span class=\"h3\">",
"     Patient related factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patient characteristics affect the PCI-related delay at which the mortality rates with PCI and fibrinolysis are equal (equipoise). The following observations were made in the large observational study of NRMI data discussed above [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/31/37369/abstract/20\">",
"     20",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Equipoise occurred at 71 minutes of PCI-related delay in patients &lt;65 years and at 155 minutes in patients &ge;65 years (",
"      <a class=\"graphic graphic_figure graphicRef67897 \" href=\"mobipreview.htm?3/1/3103\">",
"       figure 5",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef74875 \" href=\"mobipreview.htm?23/38/24171\">",
"       table 1",
"      </a>",
"      ). This means that at any PCI-related delay greater than these values, the odds of survival with PCI was no longer higher than that with fibrinolysis. This may be secondary to the fact that fibrinolysis has a greater complication rate in elderly patients.",
"     </li>",
"     <li>",
"      Equipoise occurred at 94 minutes in patients with symptom duration &le;120 minutes and 190 minutes in patients with symptom duration &gt;120 minutes. The later equipoise with longer symptom duration may reflect greater resistance to fibrinolysis in those presenting late (",
"      <a class=\"graphic graphic_figure graphicRef53374 \" href=\"mobipreview.htm?30/18/31021\">",
"       figure 2",
"      </a>",
"      ). Patients who present more than three hours after symptom onset are on the flatter portion of the survival curve for fibrinolytic therapy, where myocardial salvage and survival benefit are less time-sensitive (",
"      <a class=\"graphic graphic_figure graphicRef53374 \" href=\"mobipreview.htm?30/18/31021\">",
"       figure 2",
"      </a>",
"      ). In these patients, the advantages of PCI are likely to be retained with PCI-related delays much greater than 60 minutes. This issue is discussed in detail below. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Time from symptom onset'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Patients with anterior infarction lost the advantage of PCI at shorter PCI related delays than did patients with non-anterior infarcts (",
"      <a class=\"graphic graphic_table graphicRef74875 \" href=\"mobipreview.htm?23/38/24171\">",
"       table 1",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Because the survival benefit of primary PCI is most apparent in high-risk patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/31/37369/abstract/21,22\">",
"     21,22",
"    </a>",
"    ], the magnitude of PCI-related delay at which the survival benefit of PCI is lost probably also varies according to risk. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/16/29961?source=see_link&amp;anchor=H8#H8\">",
"     \"Primary percutaneous coronary intervention versus fibrinolysis in acute ST elevation myocardial infarction: Clinical trials\", section on 'High- versus low-risk patients'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H334601904\">",
"     'Very high-risk patients'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H190097213\">",
"    <span class=\"h3\">",
"     Non-patient related factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Non-patient related factors that appear to increase the PCI delay are door to door transfer times and off-hour presentation. In the NRMI study mentioned above, the median door-to-door transfer time was 120 minutes, as opposed to 30 minutes in randomized trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/31/37369/abstract/17\">",
"     17",
"    </a>",
"    ]. The relationship between the time that a patient presents and treatment delays was evaluated in a review of 68,439 patients treated for STEMI with either fibrinolytic therapy or primary PCI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/31/37369/abstract/23\">",
"     23",
"    </a>",
"    ]. Among patients who presented off-hours (weekdays 5 PM to 7 AM and weekends), there was a significant increase in time to treatment with PCI (door-to-balloon time 116 versus 95 minutes with presentation during regular hours), which increased the PCI-related delay since there was no increase in time to treatment for fibrinolytic therapy (34 versus 33 minutes). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/46/16106?source=see_link&amp;anchor=H152206999#H152206999\">",
"     \"Primary percutaneous coronary intervention in acute ST elevation myocardial infarction: Determinants of outcome\", section on 'Other factors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H971567377\">",
"    <span class=\"h3\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;We agree with guidelines from the American College of Cardiology",
"    <span class=\"nowrap\">",
"     Foundation/American",
"    </span>",
"    Heart Association and the European Society of Cardiology, which recommend that the first medical contact-to-device time goal should be less than 120 minutes in STEMI patients being transferred from another institution for primary PCI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/31/37369/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. Conversely, many patients in whom PCI-related delays longer than 120 minutes are anticipated may benefit from expeditious use of fibrinolytic therapy, followed by inter-institution transfer. These guidelines emphasize that hospital, operator, and patient factors should be taken into account in the process of choosing an optimal reperfusion strategy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Time from symptom onset",
"    </span>",
"    &nbsp;&mdash;&nbsp;Understanding the temporal relationship between symptom onset, reperfusion, myocardial salvage, and mortality is essential to the selection of an appropriate reperfusion strategy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/31/37369/abstract/6,7,15\">",
"     6,7,15",
"    </a>",
"    ]. The data related to this issue are presented elsewhere (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/46/16106?source=see_link&amp;anchor=H3#H3\">",
"     \"Primary percutaneous coronary intervention in acute ST elevation myocardial infarction: Determinants of outcome\", section on 'Time from symptom onset on outcomes'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/43/1721?source=see_link&amp;anchor=H69239847#H69239847\">",
"     \"Fibrinolytic therapy in acute ST elevation myocardial infarction: Initiation of therapy\", section on 'Timing'",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H262942297\">",
"    <span class=\"h3\">",
"     Presentation within 12 hours",
"    </span>",
"    &nbsp;&mdash;&nbsp;While most of the evidence presented below comes from studies of patients who present less than four to six hours after the onset of STEMI, we believe that it is reasonable to extend conclusions to patients who present up to 12 hours.",
"   </p>",
"   <p>",
"    Patients who present &le;3 hours from symptom onset are on the steep portion of the survival versus time-to-reperfusion curve (",
"    <a class=\"graphic graphic_figure graphicRef53374 \" href=\"mobipreview.htm?30/18/31021\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/31/37369/abstract/5-7\">",
"     5-7",
"    </a>",
"    ]. In this early stage, there is an opportunity for substantial myocardial salvage and mortality reduction.",
"   </p>",
"   <p>",
"    Fibrinolytic therapy has the greatest likelihood of achieving patency of the infarct related artery when patients present in the first three hours after the onset of symptoms. For those patients who cannot receive primary PCI within 90 minutes, fibrinolytic therapy has a therapeutic advantage. On the other hand, when PCI can be delivered within 90 minutes, PCI has the advantage of restoring patency in over 90 percent of patients, while fibrinolysis achieves this outcome significantly less often. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/38/7786?source=see_link&amp;anchor=H2#H2\">",
"     \"Fibrinolytic (thrombolytic) agents in acute ST elevation myocardial infarction: Markers of efficacy\", section on 'Markers'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A patient who presents early but has a significant delay during transfer and performance of PCI, may quickly move out of this window of opportunity for extensive salvage. If transfer will result in a total time from initial presentation to balloon inflation of more than 90 minutes, the patient may derive greater benefit from immediate fibrinolytic therapy. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'PCI-related delay'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The value of early reperfusion in patients presenting shortly after symptom onset was established by a meta-analysis of 22 fibrinolytic trials including 50,246 patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/31/37369/abstract/5\">",
"     5",
"    </a>",
"    ]. The absolute benefit with fibrinolytic therapy, compared to placebo or control, was greatest in patients treated within one hour of symptom onset, then fell sharply and plateaued for patients treated within one to two hours, two to three hours, and three to six hours.",
"   </p>",
"   <p>",
"    Evidence of a possible advantage of fibrinolysis over primary PCI in patients who present early comes from subgroup analyses of three randomized trials, two of which evaluated the efficacy of prehospital fibrinolysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/31/37369/abstract/24-26\">",
"     24-26",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/14/25830?source=see_link\">",
"     \"Prehospital fibrinolysis (thrombolysis) for suspected acute ST elevation myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a post hoc analysis from the CAPTIM trial of prehospital fibrinolysis versus primary PCI in 834 patients, those whose treatment assignment was made less than two hours after symptom onset had a trend toward reduced mortality with fibrinolysis (2.2 versus 5.7 percent), while those seen later had a trend toward lower mortality with primary PCI (3.7 versus 5.9 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/31/37369/abstract/24\">",
"       24",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A similar relationship of time to treatment and outcomes was noted in the MITI trial, in which 360 patients were randomly assigned to prehospital versus hospital initiated fibrinolysis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/31/37369/abstract/25\">",
"       25",
"      </a>",
"      ]. Prehospital fibrinolysis did not improve outcomes in the entire patient cohort. However, when patients were analyzed according to the time from symptom onset to treatment, those who had fibrinolysis initiated within 70 minutes of symptom onset had a significant reduction in mortality (1.2 versus 8.7 percent for those treated later). In addition, when infarct size was estimated by the percent of myocardium involved on nuclear imaging, those treated within 70 minutes had significantly smaller infarctions (4.9 versus 11.2 percent).",
"     </li>",
"     <li>",
"      In the ASSENT-3 trial, which included 5470 patients treated with fibrinolysis for acute STEMI, 25 percent of those treated within one hour of symptom onset had no enzyme elevation, defined as maximal CK &le;2 times the upper limit of normal [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/31/37369/abstract/26\">",
"       26",
"      </a>",
"      ]. In addition, these patients had smaller infarcts and improved outcomes.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For patients who present within three hours of symptom onset, the choice between fibrinolytic therapy and primary PCI depends in large part upon the anticipated delay required for primary PCI. When the delay from initial hospital presentation at PCI capable hospital to balloon inflation will be less than 90 minutes, or when the delay between presentation at a non-PCI capable hospital to balloon inflation will be less than 120 minutes, PCI is recommended [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/31/37369/abstract/8,13,27\">",
"     8,13,27",
"    </a>",
"    ]. These recommendations are consistent with those made by the American College of Cardiology",
"    <span class=\"nowrap\">",
"     Foundation/American",
"    </span>",
"    Heart Association (2013) and the European Society of Cardiology (2012) guidelines on STEMI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/31/37369/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'PCI-related delay'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/16/29961?source=see_link\">",
"     \"Primary percutaneous coronary intervention versus fibrinolysis in acute ST elevation myocardial infarction: Clinical trials\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For individuals who are treated with fibrinolytic therapy, angiography with PCI is considered for most patients. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Angiography after fibrinolysis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Approximately half of patients with STEMI present more than three to four hours after symptom onset [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/31/37369/abstract/28\">",
"     28",
"    </a>",
"    ]. Such patients are on a flatter portion of the survival versus time-to-reperfusion curve. They are usually better served by the greater efficacy and reduced stroke risk of primary PCI, despite the time required for transfer. A delay to implementation of PCI related to transfer eventually erodes the benefit of PPCI over fibrinolysis is variable and depends many factors. This PCI related delay should be &lt;90 minutes and&nbsp;preferably&nbsp;&lt;60 minutes in most cases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Presentation after 12 hours",
"    </span>",
"    &nbsp;&mdash;&nbsp;Registry data suggest that 9 to 31 percent of patients with STEMI present more than 12 hours after the onset of symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/31/37369/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. Fibrinolytic therapy administered at this time is not likely to improve outcomes, as the benefit is small (but not zero) and likely outweighed by the risks. However, primary PCI may be beneficial in selected patients. Very little evidence is available to review, as most such patients were excluded from the major primary PCI trials. The following points influence our recommendations for care in these late presenting patients:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The mortality benefit, as well as an improvement in left ventricular function from PCI likely extends beyond 12 hours, but the magnitude of this benefit is unknown. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?15/46/16106?source=see_link&amp;anchor=H269830214#H269830214\">",
"       \"Primary percutaneous coronary intervention in acute ST elevation myocardial infarction: Determinants of outcome\", section on 'Late PCI to open an occluded artery'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In many patients the onset of symptoms is unclear due to poor recall of the patients. Thus, for some patients, the true onset of STEMI may be shorter than the reported onset.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The possible indication for late (between 12 and 24 hours) primary PCI to open an occluded artery varies with the clinical status of the patient.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Symptomatic or unstable patients &mdash; There are no randomized trials or observational studies from the era of aggressive antithrombotic therapy that have addressed patients who present more than 12 hours after STEMI and who continue with evidence of ischemia. However, our experts believe that in the absence of evidence, urgent diagnostic coronary arteriography and PCI, as opposed to no reperfusion of the infarct related artery, will lead to improved outcomes. Asymptomatic patients &mdash; Randomized trials of routine late PCI have shown an improvement in left ventricular function but not in hard clinical endpoints. However, these trials included many patients who presented after 24 hours; thus, the results are not directly applicable. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?5/50/5930?source=see_link&amp;anchor=H26#H26\">",
"       \"Coronary artery patency and outcome after myocardial infarction\", section on 'Late PCI to open an occluded artery'",
"      </a>",
"      .) Our experts make the following suggestions for care of asymptomatic patients who present between 12 and 24 hours after STEMI:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Diagnostic coronary arteriography should be performed within 24 hours.",
"     </li>",
"     <li>",
"      For patients with subtotal occlusion of the infarct related artery or a totally occluded artery with collateral flow to the distal artery, our experts prefer to perform PCI.",
"     </li>",
"     <li>",
"      In patients with total occlusion and no collateral flow or in others in whom there is uncertainty as to the optimal approach, our experts suggest performing a viability study before considering PCI.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H190096540\">",
"    <span class=\"h2\">",
"     Patients for whom PCI is usually preferred",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H190096582\">",
"    <span class=\"h3\">",
"     Diagnosis in doubt",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some patients present with signs and symptoms that are suggestive but not diagnostic for STEMI. Examples include patients with non-diagnostic or borderline features of the ECG or those with an ECG suggesting STEMI but an atypical history (eg, pericarditis). In such patients the diagnosis should be confirmed with immediate echocardiography or coronary angiography, and patients at institutions that cannot perform these procedures should be transferred. Immediate PCI can then be employed as the reperfusion strategy if indicated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H190096589\">",
"    <span class=\"h3\">",
"     High risk of fibrinolytic associated bleeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fibrinolytic therapy carries a greater risk of minor and major bleeding compared to primary PCI. Intracranial hemorrhage (ICH) is the most serious of these risks and occurs in approximately 0.7 percent of patients treated with fibrinolytics [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/31/37369/abstract/13,31,32\">",
"     13,31,32",
"    </a>",
"    ]. Patients with contraindications to fibrinolysis represent a high-risk group and, although there are no randomized data specific to this population, such patients appear to benefit from primary PCI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/31/37369/abstract/29\">",
"     29",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/16/29961?source=see_link&amp;anchor=H19#H19\">",
"     \"Primary percutaneous coronary intervention versus fibrinolysis in acute ST elevation myocardial infarction: Clinical trials\", section on 'PCI when fibrinolysis is contraindicated'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Transfer for PCI is recommended by the",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    and the ESC guidelines for the following patients:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Those with absolute contraindications to fibrinolysis (",
"      <a class=\"graphic graphic_table graphicRef68784 \" href=\"mobipreview.htm?23/16/23820\">",
"       table 2",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/31/37369/abstract/13,27\">",
"       13,27",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Those with significant or multiple relative contraindications leading to an estimated intracranial hemorrhage risk &ge;4 percent (",
"      <a class=\"graphic graphic_table graphicRef62946 \" href=\"mobipreview.htm?42/52/43851\">",
"       table 3",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/31/37369/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H334601904\">",
"    <span class=\"h3\">",
"     Very high-risk patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;The benefits of primary PCI over fibrinolysis are greater in very high-risk patients and patients with cardiogenic shock (CS) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/31/37369/abstract/13,21,22,27,33\">",
"     13,21,22,27,33",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/16/29961?source=see_link&amp;anchor=H8#H8\">",
"     \"Primary percutaneous coronary intervention versus fibrinolysis in acute ST elevation myocardial infarction: Clinical trials\", section on 'High- versus low-risk patients'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/37/35418?source=see_link&amp;anchor=H28#H28\">",
"     \"Prognosis and treatment of cardiogenic shock complicating acute myocardial infarction\", section on 'Reperfusion'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This point was illustrated in an analysis of 16 randomized trials that compared primary PCI to fibrinolysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/31/37369/abstract/34\">",
"     34",
"    </a>",
"    ]. In this study, an increase in baseline mortality risk from 4.4 to 12.4 percent allowed for an increase in the acceptable PCI-related delay (equipoise) from 43 to 200 minutes.",
"   </p>",
"   <p>",
"    As a result, transfer for PCI is generally favored for patients with the following characteristics:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Severe heart failure",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      pulmonary edema.",
"     </li>",
"     <li>",
"      Those deemed to be at high risk on the basis of models such as the TIMI risk score (",
"      <a class=\"calc calc_professional\" href=\"mobipreview.htm?27/53/28497?source=see_link\">",
"       calculator 1",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/31/37369/abstract/21,22\">",
"       21,22",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients with CS represent a uniquely high-risk population. Primary percutaneous coronary intervention (PCI) is preferred to fibrinolysis for most patients with cardiogenic shock complicating acute MI. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/37/35418?source=see_link&amp;anchor=H28#H28\">",
"     \"Prognosis and treatment of cardiogenic shock complicating acute myocardial infarction\", section on 'Reperfusion'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For such patients in whom primary PCI is not immediately available, such as those who present to hospitals without on-site PCI, there is some evidence that they may benefit from administration of fibrinolytics and placement of an intraaortic balloon pump (IABP) prior to transfer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/31/37369/abstract/35\">",
"     35",
"    </a>",
"    ]. If the delay to primary PCI is greater than 120 minutes, fibrinolytic therapy should be given and the patient then transferred as soon as possible for possible PCI. Such treatment should not delay arrangements for urgent transfer and PCI. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/37/35418?source=see_link\">",
"     \"Prognosis and treatment of cardiogenic shock complicating acute myocardial infarction\"",
"    </a>",
"    .) Because of the greater mortality benefit of primary PCI over fibrinolytics in these high-risk patients, greater degrees of PCI-related delay are usually tolerated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H190097082\">",
"    <span class=\"h2\">",
"     Patients diagnosed in an ambulance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prehospital diagnosis (ambulance) of STEMI shortens the time between symptom onset to reperfusion compared to emergency room diagnosis after ambulance transport [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/31/37369/abstract/36\">",
"     36",
"    </a>",
"    ]. The factors determining outcomes with differing reperfusion strategies for such patients are similar to those for patients presenting to the emergency room of a hospital without on-site PCI capability.",
"   </p>",
"   <p>",
"    The optimal treatment strategy for patients who present early after symptom onset (within two hours) and are diagnosed in the ambulance was addressed in the WEST and CAPTIM trials, which compared prehospital fibrinolysis with urgent PCI as needed to primary PCI. Equivalent composite outcomes with the two strategies were demonstrated in both trials in which the delay between fibrinolysis and PCI was about 60 minutes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/31/37369/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. No analyses were performed to answer the question of whether there was a time cut off after one strategy performed better than another.",
"   </p>",
"   <p>",
"    The issue of early presenting patients is also discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/16/29961?source=see_link&amp;anchor=H10#H10\">",
"     \"Primary percutaneous coronary intervention versus fibrinolysis in acute ST elevation myocardial infarction: Clinical trials\", section on 'Prehospital fibrinolysis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     ANGIOGRAPHY AFTER FIBRINOLYSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;If fibrinolytic therapy is given, subsequent angiography with PCI is appropriate for many patients prior to discharge. The optimal timing of routine angiography and possible PCI after fibrinolytic therapy for STEMI is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/42/34473?source=see_link&amp;anchor=H15#H15\">",
"     \"Percutaneous coronary intervention after fibrinolysis for acute ST elevation myocardial infarction\", section on 'Adjunctive or early elective PCI'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are four situations in which the evidence supports angiography followed by PCI within 24 hours of fibrinolytic therapy:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For failed fibrinolysis or threatened reocclusion, as manifested by findings such as persistent or recurrent chest pain, ST segment elevation, or hemodynamic or electrical instability. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?8/27/8634?source=see_link\">",
"       \"Management of failed fibrinolysis (thrombolysis) or threatened reocclusion in acute ST elevation myocardial infarction\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/42/34473?source=see_link\">",
"       \"Percutaneous coronary intervention after fibrinolysis for acute ST elevation myocardial infarction\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients in cardiogenic shock who present to a facility without primary PCI capability represent a situation in which PCI should be carried out as soon as possible after initial treatment with fibrinolytics. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?34/37/35418?source=see_link&amp;anchor=H28#H28\">",
"       \"Prognosis and treatment of cardiogenic shock complicating acute myocardial infarction\", section on 'Reperfusion'",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H334601904\">",
"       'Very high-risk patients'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      As part of a pharmacoinvasive strategy in which fibrinolytic therapy is followed by patient transfer to an interventional center for angiography and PCI. The delay to PCI (because of the transfer process) normally precludes a primary PCI approach, so fibrinolytic therapy is utilized to provide possible reperfusion prior to planned PCI following patient transfer. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/42/34473?source=see_link&amp;anchor=H1293488#H1293488\">",
"       \"Percutaneous coronary intervention after fibrinolysis for acute ST elevation myocardial infarction\", section on 'Pharmacoinvasive strategy'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      In high-risk patients, the angiogram and PCI are completed between three and six hours.",
"     </li>",
"     <li>",
"      In low-risk patients, our experts suggest coronary angiography between 3 and 24 hours. It is also reasonable to perform coronary arteriography after 24 hours (but before discharge) or noninvasive risk stratification prior to determine if coronary arteriography is warranted.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     ADJUNCTIVE THERAPIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients treated with either fibrinolytic therapy or primary PCI for STEMI should also receive other therapies aimed at improving coronary perfusion. These therapies include an antithrombin (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    , low molecular weight heparin, or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/48/18184?source=see_link\">",
"     bivalirudin",
"    </a>",
"    ) and aggressive antiplatelet therapy (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    , and, in patients undergoing primary PCI, a glycoprotein",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitor). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/41/44697?source=see_link\">",
"     \"Overview of the acute management of ST elevation myocardial infarction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/49/35610?source=see_link\">",
"     \"Antiplatelet agents in acute ST elevation myocardial infarction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/57/5018?source=see_link\">",
"     \"Anticoagulant therapy in acute ST elevation myocardial infarction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/62/31721?source=see_link&amp;anchor=H24756062#H24756062\">",
"     \"Primary percutaneous coronary intervention in acute ST elevation myocardial infarction: Periprocedural management\", section on 'Adjunctive therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     ROLE OF CABG",
"    </span>",
"    &nbsp;&mdash;&nbsp;Coronary artery bypass graft surgery (CABG) is infrequently performed in patients with an STEMI. The main indications for emergent or urgent CABG are related to failure of fibrinolysis or PCI, cardiogenic shock, or life threatening ventricular arrhythmias in the setting of left main or three-vessel coronary artery disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/31/37369/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The benefit of revascularization must be weighed against the increase in mortality after CABG in the first three to seven days after STEMI. Thus, if the patient can be medically stabilized, surgery should be delayed to allow myocardial recovery. Patients with critical anatomy should undergo CABG during the initial hospitalization. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/22/6505?source=see_link\">",
"     \"Coronary artery bypass graft surgery after acute ST elevation myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Coronary artery reperfusion with either primary percutaneous coronary intervention (PCI) or fibrinolytic therapy improves clinical outcomes compared to no reperfusion in nearly all groups of patients with an acute ST elevation myocardial infarction (STEMI). For STEMI patients who present between 0 and 12 hours after symptom onset, we recommend reperfusion with either primary PCI or fibrinolysis (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Primary PCI (when delivered in a timely manner by expert healthcare providers), compared to fibrinolysis, leads to lower rates of death and recurrent myocardial infarction, as well as smaller infarcts. (See",
"    <a class=\"local\" href=\"#H1\">",
"     'Introduction'",
"    </a>",
"    above.)",
"    <br/>",
"    <br/>",
"    The decision to choose fibrinolytic therapy generally results when a patient presents to a setting in which expert primary PCI is not available within the time parameters recommended below. However, these time cut-offs are not rigid and a higher tolerance for delay in getting a patient to primary PCI may be needed for higher-risk patients or those at risk for fibrinolytic associated bleeding. (See",
"    <a class=\"local\" href=\"#H334599427\">",
"     'Factors determining choice of reperfusion strategy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The following recommendations apply to patients who present within 12 hours of symptom onset:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For patients who are transported to or arrive at a PCI-capable hospital, we recommend primary PCI, rather than fibrinolysis, as long as it can be performed with a door-to-balloon time 90 minutes or less (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      For patients who are transported to or arrive at a hospital not capable of immediate PCI, we recommend immediate transfer to a PCI capable hospital for primary PCI rather than fibrinolysis at the first hospital, as long as it can be performed with a first medical contact to PCI time of less than 120 minutes (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      For those patients in whom the decision remains unclear after consideration of the above recommendations, we believe it is reasonable to prefer primary PCI. Reasons for this suggestion include the hemorrhagic risk associated with fibrinolytic therapy, as well as the likely need for PCI after fibrinolysis. (See",
"      <a class=\"local\" href=\"#H190096540\">",
"       'Patients for whom PCI is usually preferred'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      PCI is preferred to fibrinolysis, with less emphasis placed upon time to presentation and PCI-related delay in patients with markers of high mortality risk, such as Killip class three or four, or a TIMI risk score &ge;5 (",
"      <a class=\"calc calc_professional\" href=\"mobipreview.htm?27/53/28497?source=see_link\">",
"       calculator 1",
"      </a>",
"      ), are more likely to benefit from primary PCI than fibrinolysis. In addition, the benefits of primary PCI over fibrinolysis are probably retained at greater degrees of PCI-related delay in these patients. We recommend primary PCI for high-risk patients (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H334601904\">",
"       'Very high-risk patients'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      While the optimal strategy for the management of patients in cardiogenic shock is unknown, the rapid restoration of blood flow improves outcomes. Primary PCI is the preferred reperfusion strategy in most of these patients, although fibrinolysis prior to transfer to an institution with on-site PCI may be of benefit. Recommendations for the use of reperfusion therapy in patients with cardiogenic shock are found separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?34/37/35418?source=see_link&amp;anchor=H42#H42\">",
"       \"Prognosis and treatment of cardiogenic shock complicating acute myocardial infarction\", section on 'Summary and Recommendations'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients who have received fibrinolysis and have high-risk features including but not limited to anterior MI, Killip class &ge;2, inferior MI with evidence of right ventricular involvement, systolic blood pressure of less than 100 mmHg, heart rate &gt;100",
"      <span class=\"nowrap\">",
"       beats/min,",
"      </span>",
"      we recommend immediate transfer to a PCI capable hospital (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). Due to the possibility of reocclusion after apparently successful fibrinolysis, we suggest transfer of all lower risk patients who have received fibrinolytic therapy, either in a non-PCI hospital or in an ambulance, to a PCI capable hospital (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). The subsequent management of these patients, and those with threatened reocclusion, is discussed above. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Angiography after fibrinolysis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The following recommendations apply to patients who present after 12 hours of symptom onset:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For patients who present between 12 and 36 hours after symptom onset and have severe heart failure, hemodynamic or electrical instability, or persistent ischemic symptoms, we recommend primary PCI, as opposed to no reperfusion therapy (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Presentation after 12 hours'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend not using fibrinolytic therapy for patients who present between 12 and 36 hours, including those for whom PCI is recommended but not employed (eg, patient refusal or PCI not available) (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/31/37369/abstract/1\">",
"      Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC), Steg PG, James SK, et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 2012; 33:2569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/31/37369/abstract/2\">",
"      O'Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2013; 127:e362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/31/37369/abstract/3\">",
"      O'Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2013; 127:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/31/37369/abstract/4\">",
"      Anderson JL, Karagounis LA, Califf RM. Metaanalysis of five reported studies on the relation of early coronary patency grades with mortality and outcomes after acute myocardial infarction. Am J Cardiol 1996; 78:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/31/37369/abstract/5\">",
"      Boersma E, Maas AC, Deckers JW, Simoons ML. Early thrombolytic treatment in acute myocardial infarction: reappraisal of the golden hour. Lancet 1996; 348:771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/31/37369/abstract/6\">",
"      Gersh BJ, Stone GW, White HD, Holmes DR Jr. Pharmacological facilitation of primary percutaneous coronary intervention for acute myocardial infarction: is the slope of the curve the shape of the future? JAMA 2005; 293:979.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/31/37369/abstract/7\">",
"      Huber K, De Caterina R, Kristensen SD, et al. Pre-hospital reperfusion therapy: a strategy to improve therapeutic outcome in patients with ST-elevation myocardial infarction. Eur Heart J 2005; 26:2063.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/31/37369/abstract/8\">",
"      Bassand JP, Danchin N, Filippatos G, et al. Implementation of reperfusion therapy in acute myocardial infarction. A policy statement from the European Society of Cardiology. Eur Heart J 2005; 26:2733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/31/37369/abstract/9\">",
"      Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet 2003; 361:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/31/37369/abstract/10\">",
"      Boersma E, Primary Coronary Angioplasty vs. Thrombolysis Group. Does time matter? A pooled analysis of randomized clinical trials comparing primary percutaneous coronary intervention and in-hospital fibrinolysis in acute myocardial infarction patients. Eur Heart J 2006; 27:779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/31/37369/abstract/11\">",
"      Stone GW. Angioplasty strategies in ST-segment-elevation myocardial infarction: part I: primary percutaneous coronary intervention. Circulation 2008; 118:538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/31/37369/abstract/12\">",
"      Henry TD, Unger BT, Sharkey SW, et al. Design of a standardized system for transfer of patients with ST-elevation myocardial infarction for percutaneous coronary intervention. Am Heart J 2005; 150:373.",
"     </a>",
"    </li>",
"    <li>",
"     Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction. www.acc.org/qualityandscience/clinical/statements.htm (Accessed on August 24, 2006).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/31/37369/abstract/14\">",
"      Armstrong PW, Collen D, Antman E. Fibrinolysis for acute myocardial infarction: the future is here and now. Circulation 2003; 107:2533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/31/37369/abstract/15\">",
"      Gersh BJ, Antman EM. Selection of the optimal reperfusion strategy for STEMI: does time matter? Eur Heart J 2006; 27:761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/31/37369/abstract/16\">",
"      Nallamothu BK, Bates ER. Percutaneous coronary intervention versus fibrinolytic therapy in acute myocardial infarction: is timing (almost) everything? Am J Cardiol 2003; 92:824.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/31/37369/abstract/17\">",
"      Nallamothu BK, Bates ER, Herrin J, et al. Times to treatment in transfer patients undergoing primary percutaneous coronary intervention in the United States: National Registry of Myocardial Infarction (NRMI)-3/4 analysis. Circulation 2005; 111:761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/31/37369/abstract/18\">",
"      Brodie BR, Gersh BJ, Stuckey T, et al. When is door-to-balloon time critical? Analysis from the HORIZONS-AMI (Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction) and CADILLAC (Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications) trials. J Am Coll Cardiol 2010; 56:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/31/37369/abstract/19\">",
"      Pinto DS, Frederick PD, Chakrabarti AK, et al. Benefit of transferring ST-segment-elevation myocardial infarction patients for percutaneous coronary intervention compared with administration of onsite fibrinolytic declines as delays increase. Circulation 2011; 124:2512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/31/37369/abstract/20\">",
"      Pinto DS, Kirtane AJ, Nallamothu BK, et al. Hospital delays in reperfusion for ST-elevation myocardial infarction: implications when selecting a reperfusion strategy. Circulation 2006; 114:2019.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/31/37369/abstract/21\">",
"      Thune JJ, Hoefsten DE, Lindholm MG, et al. Simple risk stratification at admission to identify patients with reduced mortality from primary angioplasty. Circulation 2005; 112:2017.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/31/37369/abstract/22\">",
"      Kent DM, Schmid CH, Lau J, Selker HP. Is primary angioplasty for some as good as primary angioplasty for all? J Gen Intern Med 2002; 17:887.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/31/37369/abstract/23\">",
"      Magid DJ, Wang Y, Herrin J, et al. Relationship between time of day, day of week, timeliness of reperfusion, and in-hospital mortality for patients with acute ST-segment elevation myocardial infarction. JAMA 2005; 294:803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/31/37369/abstract/24\">",
"      Steg PG, Bonnefoy E, Chabaud S, et al. Impact of time to treatment on mortality after prehospital fibrinolysis or primary angioplasty: data from the CAPTIM randomized clinical trial. Circulation 2003; 108:2851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/31/37369/abstract/25\">",
"      Weaver WD, Cerqueira M, Hallstrom AP, et al. Prehospital-initiated vs hospital-initiated thrombolytic therapy. The Myocardial Infarction Triage and Intervention Trial. JAMA 1993; 270:1211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/31/37369/abstract/26\">",
"      Taher T, Fu Y, Wagner GS, et al. Aborted myocardial infarction in patients with ST-segment elevation: insights from the Assessment of the Safety and Efficacy of a New Thrombolytic Regimen-3 Trial Electrocardiographic Substudy. J Am Coll Cardiol 2004; 44:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/31/37369/abstract/27\">",
"      Van de Werf F, Ardissino D, Betriu A, et al. Management of acute myocardial infarction in patients presenting with ST-segment elevation. The Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J 2003; 24:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/31/37369/abstract/28\">",
"      McGinn AP, Rosamond WD, Goff DC Jr, et al. Trends in prehospital delay time and use of emergency medical services for acute myocardial infarction: experience in 4 US communities from 1987-2000. Am Heart J 2005; 150:392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/31/37369/abstract/29\">",
"      Grzybowski M, Clements EA, Parsons L, et al. Mortality benefit of immediate revascularization of acute ST-segment elevation myocardial infarction in patients with contraindications to thrombolytic therapy: a propensity analysis. JAMA 2003; 290:1891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/31/37369/abstract/30\">",
"      Eagle KA, Goodman SG, Avezum A, et al. Practice variation and missed opportunities for reperfusion in ST-segment-elevation myocardial infarction: findings from the Global Registry of Acute Coronary Events (GRACE). Lancet 2002; 359:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/31/37369/abstract/31\">",
"      Gore JM, Granger CB, Simoons ML, et al. Stroke after thrombolysis. Mortality and functional outcomes in the GUSTO-I trial. Global Use of Strategies to Open Occluded Coronary Arteries. Circulation 1995; 92:2811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/31/37369/abstract/32\">",
"      Huynh T, Cox JL, Massel D, et al. Predictors of intracranial hemorrhage with fibrinolytic therapy in unselected community patients: a report from the FASTRAK II project. Am Heart J 2004; 148:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/31/37369/abstract/33\">",
"      Morrow DA, Antman EM, Charlesworth A, et al. TIMI risk score for ST-elevation myocardial infarction: A convenient, bedside, clinical score for risk assessment at presentation: An intravenous nPA for treatment of infarcting myocardium early II trial substudy. Circulation 2000; 102:2031.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/31/37369/abstract/34\">",
"      Tarantini G, Razzolini R, Napodano M, et al. Acceptable reperfusion delay to prefer primary angioplasty over fibrin-specific thrombolytic therapy is affected (mainly) by the patient's mortality risk: 1 h does not fit all. Eur Heart J 2010; 31:676.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/31/37369/abstract/35\">",
"      French JK, Feldman HA, Assmann SF, et al. Influence of thrombolytic therapy, with or without intra-aortic balloon counterpulsation, on 12-month survival in the SHOCK trial. Am Heart J 2003; 146:804.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/31/37369/abstract/36\">",
"      Ortolani P, Marzocchi A, Marrozzini C, et al. Clinical impact of direct referral to primary percutaneous coronary intervention following pre-hospital diagnosis of ST-elevation myocardial infarction. Eur Heart J 2006; 27:1550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/31/37369/abstract/37\">",
"      Bonnefoy E, Lapostolle F, Leizorovicz A, et al. Primary angioplasty versus prehospital fibrinolysis in acute myocardial infarction: a randomised study. Lancet 2002; 360:825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/31/37369/abstract/38\">",
"      Armstrong PW, WEST Steering Committee. A comparison of pharmacologic therapy with/without timely coronary intervention vs. primary percutaneous intervention early after ST-elevation myocardial infarction: the WEST (Which Early ST-elevation myocardial infarction Therapy) study. Eur Heart J 2006; 27:1530.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 80 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-203.80.222.8-3836C529BC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_31_37369=[""].join("\n");
var outline_f36_31_37369=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H22\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GENERAL ISSUES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H334599427\">",
"      FACTORS DETERMINING CHOICE OF REPERFUSION STRATEGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      PCI-related delay",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H334596199\">",
"      - Patient related factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H190097213\">",
"      - Non-patient related factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H971567377\">",
"      - Summary",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Time from symptom onset",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H262942297\">",
"      - Presentation within 12 hours",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Presentation after 12 hours",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H190096540\">",
"      Patients for whom PCI is usually preferred",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H190096582\">",
"      - Diagnosis in doubt",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H190096589\">",
"      - High risk of fibrinolytic associated bleeding",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H334601904\">",
"      - Very high-risk patients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H190097082\">",
"      Patients diagnosed in an ambulance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      ANGIOGRAPHY AFTER FIBRINOLYSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      ADJUNCTIVE THERAPIES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      ROLE OF CABG",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/80\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/80|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?15/40/16013\" title=\"figure 1\">",
"      Mortality after thrombolysis based on TIMI flow",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?30/18/31021\" title=\"figure 2\">",
"      Mortality and time to reperfusion in MI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?8/37/8798\" title=\"figure 3\">",
"      PCI related delay and mortality",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?9/33/9758\" title=\"figure 4\">",
"      PCI related delay and death, MI, and stroke",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?3/1/3103\" title=\"figure 5\">",
"      PCI related delay and risk of death",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/80|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/38/24171\" title=\"table 1\">",
"      Time at which PCI loses survival superiority over fibrinolysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/16/23820\" title=\"table 2\">",
"      Contraindications to fibrinolytic therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?42/52/43851\" title=\"table 3\">",
"      Risk factors for intracranial hemorrhage with thrombolysis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"mobipreview.htm?27/53/28497?source=related_link\" title=\"calculator 1\">",
"      Calculator: Thrombolysis in Myocardial Infarction (TIMI) score for ST elevation acute myocardial infarction",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/57/5018?source=related_link\">",
"      Anticoagulant therapy in acute ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/49/35610?source=related_link\">",
"      Antiplatelet agents in acute ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/1/29722?source=related_link\">",
"      Coronary arteriography and revascularization for unstable angina or non-ST elevation acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/22/6505?source=related_link\">",
"      Coronary artery bypass graft surgery after acute ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/50/5930?source=related_link\">",
"      Coronary artery patency and outcome after myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/38/7786?source=related_link\">",
"      Fibrinolytic (thrombolytic) agents in acute ST elevation myocardial infarction: Markers of efficacy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/43/1721?source=related_link\">",
"      Fibrinolytic therapy in acute ST elevation myocardial infarction: Initiation of therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/27/8634?source=related_link\">",
"      Management of failed fibrinolysis (thrombolysis) or threatened reocclusion in acute ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/41/44697?source=related_link\">",
"      Overview of the acute management of ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/42/34473?source=related_link\">",
"      Percutaneous coronary intervention after fibrinolysis for acute ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/14/25830?source=related_link\">",
"      Prehospital fibrinolysis (thrombolysis) for suspected acute ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/46/16106?source=related_link\">",
"      Primary percutaneous coronary intervention in acute ST elevation myocardial infarction: Determinants of outcome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/62/31721?source=related_link\">",
"      Primary percutaneous coronary intervention in acute ST elevation myocardial infarction: Periprocedural management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/16/29961?source=related_link\">",
"      Primary percutaneous coronary intervention versus fibrinolysis in acute ST elevation myocardial infarction: Clinical trials",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/37/35418?source=related_link\">",
"      Prognosis and treatment of cardiogenic shock complicating acute myocardial infarction",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_31_37370="AF via multiple AV connections";
var content_f36_31_37370=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F71133&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F71133&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1147px;\">",
"  <div class=\"figure\" style=\"width: 561px\">",
"   <div class=\"ttl\">",
"    Preexcited tachycardia during atrial fibrillation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 541px; height: 304px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The ventricular rate in this irregularly irregular arrhythmia is extremely rapid, approaching 500 beats/min. The QRS complexes are wide or aberrant and have variable morphologies, suggesting that there are multiple accessory atrioventricular connections. At electrophysiologic study left posterior and left lateral pathways were identified and successfully ablated.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Morton Arnsdorf, MD.",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 466px\">",
"   <div class=\"ttl\">",
"    Normal ECG",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 466px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Normal sinus rhythm at a rate of 71 beats/min, a P wave axis of 45&deg;, and a PR interval of 0.15 sec.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Morton Arnsdorf, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_31_37370=[""].join("\n");
var outline_f36_31_37370=null;
var title_f36_31_37371="Risk factors for VAP";
var content_f36_31_37371=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F67276&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F67276&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Risk factors predisposing to ventilator-associated pneumonia (VAP)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Witnessed aspiration",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chronic obstructive pulmonary disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Administration of antacids or histamine type-2 antagonists",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Supine positioning",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Coma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Enteral nutrition",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nasal intubation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sinusitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nasogastric tube",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Reintubation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tracheostomy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Patient transport",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Duration of mechanical ventilation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Acute respiratory distress syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chronic obstructive pulmonary disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Multiple organ system failure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Prior antibiotic exposure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Age &gt;60 years",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Head trauma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Presence of intracranial pressure monitoring",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fall or winter season",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Daily ventilator circuit changes",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_31_37371=[""].join("\n");
var outline_f36_31_37371=null;
var title_f36_31_37372="Clinical series of miliary TB";
var content_f36_31_37372=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F77719&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F77719&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Major clinical series of miliary tuberculosis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        First author, year",
"       </td>",
"       <td class=\"subtitle1\">",
"        Years included",
"       </td>",
"       <td class=\"subtitle1\">",
"        Location",
"       </td>",
"       <td class=\"subtitle1\">",
"        Inclusion criteria",
"       </td>",
"       <td class=\"subtitle1\">",
"        # of patients",
"       </td>",
"       <td class=\"subtitle1\">",
"        Percent male",
"       </td>",
"       <td class=\"subtitle1\">",
"        Race, percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Maartens, 1990",
"       </td>",
"       <td>",
"        1978-87",
"       </td>",
"       <td>",
"        Groote Schuur Hospital (Community based teaching hospital in South Africa)",
"       </td>",
"       <td>",
"        Miliary pattern on CXR plus MTB on culture from any site; or biopsy or autopsy evidence of miliary organ involvement with TB",
"       </td>",
"       <td>",
"        109",
"       </td>",
"       <td>",
"        51",
"       </td>",
"       <td>",
"        African, 45, mixed, 49, white, 6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Kim, 1990",
"       </td>",
"       <td>",
"        1975-88",
"       </td>",
"       <td>",
"        Duke University Medical Center and Durham VA Hospital Durham, North Carolina",
"       </td>",
"       <td>",
"        Discharge diagnosis of disseminated or miliary TB",
"       </td>",
"       <td>",
"        38",
"       </td>",
"       <td>",
"        50",
"       </td>",
"       <td>",
"        African-American, 50*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"4\">",
"        Gelb, 1973",
"       </td>",
"       <td colspan=\"1\" rowspan=\"4\">",
"        1960-70",
"       </td>",
"       <td colspan=\"1\" rowspan=\"4\">",
"        UCLA Hospital Los Angeles, California",
"       </td>",
"       <td>",
"        Miliary pattern on CXR and one or more:",
"       </td>",
"       <td colspan=\"1\" rowspan=\"4\">",
"        109",
"       </td>",
"       <td colspan=\"1\" rowspan=\"4\">",
"        59",
"       </td>",
"       <td colspan=\"1\" rowspan=\"4\">",
"        African-American, 81",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1. MTB on culture,",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2. Biopsy or autopsy showing caseating granulomas with AFB,",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3. Clinical presentation and response consistent with TB",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Munt, 1971",
"       </td>",
"       <td>",
"        1954-70",
"       </td>",
"       <td>",
"        Sanitorium drawing from eastern part of North Carolina",
"       </td>",
"       <td>",
"        \"Acute, diffuse pulmonary and extra-pulmonary dissemination",
"of TB, usually associated with a miliary pattern on CXR, with either",
"MTB by culture or response to TB therapy\"",
"       </td>",
"       <td>",
"        69",
"       </td>",
"       <td>",
"        65",
"       </td>",
"       <td>",
"        African-American, 87",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Proudfoot, 1969",
"       </td>",
"       <td>",
"        1954-67",
"       </td>",
"       <td>",
"        Edinburgh, Scotland",
"       </td>",
"       <td>",
"        \"Adults diagnosed in Edinburgh as having disseminated TB\"",
"       </td>",
"       <td>",
"        40",
"       </td>",
"       <td>",
"        40",
"       </td>",
"       <td>",
"        Non-British, &lt;1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Biehl, 1957",
"       </td>",
"       <td>",
"        1951-56",
"       </td>",
"       <td>",
"        Cincinatti General (City teaching hospital Cincinatti, Ohio)",
"       </td>",
"       <td>",
"        Bacteriologic or pathologic diagnosis of miliary tuberculosis or probable diagnosis with response to therapy",
"       </td>",
"       <td>",
"        68",
"       </td>",
"       <td>",
"        69",
"       </td>",
"       <td>",
"        African-American, 23",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Excluding VA population.",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Nesli Basgoz, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_31_37372=[""].join("\n");
var outline_f36_31_37372=null;
var title_f36_31_37373="Endemic malaria in Africa";
var content_f36_31_37373=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F59126&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=8\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F59126&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=8\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    African countries with endemic malaria",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Country",
"       </td>",
"       <td class=\"subtitle1\">",
"        Areas at risk, season",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Angola",
"       </td>",
"       <td>",
"        Nationwide, throughout the year.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Benin",
"       </td>",
"       <td>",
"        Nationwide, throughout the year.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Burkina Faso",
"       </td>",
"       <td>",
"        Nationwide, throughout the year.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Burundi",
"       </td>",
"       <td>",
"        Nationwide, throughout the year.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cameroon",
"       </td>",
"       <td>",
"        Nationwide, throughout the year.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cape Verde",
"       </td>",
"       <td>",
"        Risk is limited to S&atilde;o",
"Tiago Island from",
"September through November.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Central African Republic",
"       </td>",
"       <td>",
"        Nationwide, throughout the year.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chad",
"       </td>",
"       <td>",
"        Nationwide, throughout the year.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Comoros",
"       </td>",
"       <td>",
"        Nationwide, throughout the year.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Congo",
"       </td>",
"       <td>",
"        Nationwide, throughout the year.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        C&ocirc;te d'Ivoire",
"       </td>",
"       <td>",
"        Nationwide, throughout the year.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Democratic Republic of Congo (Za&iuml;re)",
"       </td>",
"       <td>",
"        Nationwide, throughout the year.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Djibouti",
"       </td>",
"       <td>",
"        Nationwide, throughout the year.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Equatorial Guinea",
"       </td>",
"       <td>",
"        Nationwide, throughout the year.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Eritrea",
"       </td>",
"       <td>",
"        Nationwide except above 2000 m, throughout the year.",
"There is no risk in Asmara.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ethiopia",
"       </td>",
"       <td>",
"        Nationwide except above 2000 m, throughout the year.",
"There is no malaria risk in Addis Ababa.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gabon",
"       </td>",
"       <td>",
"        Nationwide, throughout the year.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gambia",
"       </td>",
"       <td>",
"        Nationwide, throughout the year.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ghana",
"       </td>",
"       <td>",
"        Nationwide, throughout the year.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Guinea",
"       </td>",
"       <td>",
"        Nationwide, throughout the year.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Guinea Bissau",
"       </td>",
"       <td>",
"        Nationwide, throughout the year.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Kenya",
"       </td>",
"       <td>",
"        Nationwide, throughout the year. There is normally",
"little risk in Nairobi and at altitudes above 2500 m in Central, Rift",
"Valley, Eastern, Nyanza and Western Provinces.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Liberia",
"       </td>",
"       <td>",
"        Nationwide, throughout the year.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Madagascar",
"       </td>",
"       <td>",
"        Nationwide, throughout the year.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Malawi",
"       </td>",
"       <td>",
"        Nationwide, throughout the year.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mali",
"       </td>",
"       <td>",
"        Nationwide, throughout the year.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mauritania",
"       </td>",
"       <td>",
"        Nationwide, throughout the year, except in the northern",
"areas of Dakhlet, Nouadhibou and Tiris Zemour. In Adrar and Inchiri there",
"is malaria risk during the rainy season (July through October).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mauritius",
"       </td>",
"       <td>",
"        Risk only in certain rural areas. There is no risk on",
"Rodrigues Island.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mozambique",
"       </td>",
"       <td>",
"        Nationwide, throughout the year.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Niger",
"       </td>",
"       <td>",
"        Nationwide, throughout the year.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nigeria",
"       </td>",
"       <td>",
"        Nationwide, throughout the year.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rwanda",
"       </td>",
"       <td>",
"        Nationwide, throughout the year.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sao Tome &amp; Principe",
"       </td>",
"       <td>",
"        Nationwide, throughout the year.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Senegal",
"       </td>",
"       <td>",
"        Nationwide, throughout the year. There is less risk",
"from January through June in the central western regions.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sierra Leone",
"       </td>",
"       <td>",
"        Nationwide, throughout the year.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Somalia",
"       </td>",
"       <td>",
"        Nationwide, throughout the year.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sudan",
"       </td>",
"       <td>",
"        Nationwide, throughout the year. The risk is low and",
"seasonal in the north and higher along the Nile south of Lake Nasser",
"and central and southern part of the country. Risk on the Red Sea coast",
"is very limited.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tanzania",
"       </td>",
"       <td>",
"        Nationwide below 1800 m, throughout the year.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Togo",
"       </td>",
"       <td>",
"        Nationwide, throughout the year.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Uganda",
"       </td>",
"       <td>",
"        Nationwide, throughout the year, including the main",
"towns of Fort Portal, Jinja, Kampala, Mbale and parts of Kigezi.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Zambia",
"       </td>",
"       <td>",
"        Nationwide, throughout the year.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Zimbabwe",
"       </td>",
"       <td>",
"        Risk from November through June in areas below 1200 m",
"and throughout the year in the Zambezi valley. In Harare and Bulawayo,",
"the risk is negligible.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_31_37373=[""].join("\n");
var outline_f36_31_37373=null;
var title_f36_31_37374="Equianalgesic opioid doses B";
var content_f36_31_37374=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F67175&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F67175&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 522px\">",
"   <div class=\"ttl\">",
"    Equianalgesic conversion example",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 502px; height: 231px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A patient is on sustained release (SR) oxycodone 20 mg po q12h and oxycodone/acetaminophen 5/325 mg 1 tab po q3-4h prn for breakthrough pain. The patient's pain has been well controlled on this regimen as only 1 oxycodone/acetaminophen tablet has been required for breakthrough every day. Oral administration has become contraindicated in this patient and you wish to convert the pain management regimen to ao continuous IV infusion of morphine.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Pain Management Tables and Guidelines. Dana Farber Cancer Institute/Brigham and Women's Hospital Pain and Pallitative Care Program. Copyright &copy; 2004.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_31_37374=[""].join("\n");
var outline_f36_31_37374=null;
var title_f36_31_37375="Percutaneous treatment of endograft limb thrombosis";
var content_f36_31_37375=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F61381&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F61381&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Percutaneous treatment of endograft limb thrombosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 249px; height: 370px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The thrombosis of the left limb of the endograft (red arrow) was succesfully treated percutaneously with with thrombolysis, angioplasty, and stent placement.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_31_37375=[""].join("\n");
var outline_f36_31_37375=null;
         